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INTRODUCTION 
             Nanotechnology, the term invented by Norio taniguchi in 1974 at the 
University of Tokyo, provides opportunities to assimilate science and technology 
in life and physical sciences at nanolevel. Nanotechnology is the integration of 
science and engineering disciplines to produce products either with or containing 
nanoscale particles. Thus, it is applied in various areas of biomedical sciences. 
Indeed, this technology helps to improve the innovation of biomarkers, helps in 
molecular diagnosis, drug delivery, regenerative medicine, cellular trafficking, bio 
imaging and gene delivery. 
   The US FDA specifies that nanotechnology involves: research and 
technology development at atomic, molecular or macromolecular levels, in the 
length scale of approximately 1-100 nm ; creating and using structures, devices 
and systems that have novel properties and functions because of their small and/or 
intermediate size; and the ability to control or manipulate on atomic scale. 
Nanoparticles have range of potential application in short term in new cosmetics, 
textiles and paints. These technologies can increase the potency of traditional 
small molecules of drugs in addition to potentially providing a mechanism for 
treating previously incurable diseases (Shinde et al., 2012). 
               Nanoparticles are sub-nanosized colloidal structures composed of natural 
or synthetic or semi synthetic polymer. The first reported nanoparticles were 
based on non-biodegradable polymeric systems (polyacrylamide, polymethyl-
methacrylate and polystyrene etc.) (Birrenbach and Speiser, 1976; Kreuter and 
Speiser, 1976) The polymeric nanoparticles can carry drug(s) or proteinaceous 
substances, i.e. antigen(s). These bioactive are entrapped in the polymer matrix as 
particulates enmesh or solid solution or may be bound to the particle surface by 
physical adsorption or chemical. 
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Nanomedicine is a subset of nanotechnology, they use tiny particles which 
are more than 10 million times smaller when compared to human body. In 
nanomedicine, particles are very smaller than the living cell and due to this, 
nanomedicine has many revolutionary opportunities in fighting against all  
types of cancer, neurodegenerative disorders and even other diseases  
(Shinde et al.,2012). 
The emergence of nanotechnology has made a significant impact on 
clinical therapeutics in the last two decades. Advances in bio compatible 
nanoscale drug carriers such as liposomes and polymeric nanparticles have 
enabled more efficient and safer delivery of a myriad of drugs. Advantages in 
nanoparticle drug delivery, particularly at the systemic level, include longer 
circulation half-lives, improved pharmaco kinetics and reduced side effects.  In 
cancer treatments, nanoparticles can further rely on the enhanced permeability and 
retention effect caused by leaky tumor vasculatures for better drug accumulation 
at the tumor sites. These benefits have made therapeutic nanoparticles a promising 
candidate to replace traditional chemotherapy, where intravenous injection of 
toxic agents poses a serious threat to healthy tissues and results in dose-limiting 
side effects. Currently, several nanoparticle-based chemotherapeutics have 
emerged on the market, while many are undergoing various stages of clinical or 
preclinical development. 
 Mainly there are two types of nanoparticles, They are 
1)  Nanospheres - A matrix type like structure in which drug is dispersed in 
 polymer matrix. 
2)  Nanocapsule - In this drug is encapsulated in central volume surrounded 
by continuous polymeric sheath (Nagavarma et al., 2012). 
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Figure: 1 Various type of nanoparticles 
Advantages of Nanoparticles 
 Easy preparation.  
 They are targeted drug delivery. 
 Due to their small size, they penetrate small capillary and taken by the 
 cells which allows drug accumulation at target sites in the body.  
 They have a good control over size and size distribution.  
 They have good protection of the encapsulated drug.  
 They have a longer clearance time.  
 They have a high therapeutic efficacy.  
 They have high bioavailability.  
 Stable dosage forms of drug which are either unstable or have 
 unacceptably low bioavailability in non nano particulate dosages forms. 
 Increased surface area results in faster dissolution of active agents in an 
 aqueous environment. 
 They have faster dissolution that equates to greater bioavailability. 
 Smaller drug doses are enough.  
 There is a reduction in fed/fasted variability. 
 Less toxic in nature (Shinde et al., 2012). 
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Disadvantages of Nanoparticles 
 Extensive use of polyvinyl alcohol as a detergent.  
 There are Issues with toxicity. 
 There are limited targeting abilities. 
 Discontinuation of therapy is impossible. 
 They produce cytotoxicity.  
 They can cause pulmonary inflammation and pulmonary carcinogenicity. 
 They can even cause Alveloarar inflammation. 
 The disturbance of autonomic balance caused by nanoparticles have direct 
 effect on heart and vascular function (Shinde et al.,2012). 
Properties of Nanoparticles 
 Due to their smaller size, the nanoparticles readily disperse in water 
 forming a clear colloidal dispersion and is suitable for injection via fine 
 gauge  needles. 
 The preparation is very sterile and a pyrogenic. 
 No gross change can occurs when gelatin nanoparticles are autoclaved at 
 121°C for 15 mins. 
 By experimental data, it is found that the nanoparticles are non-antigenic. 
Physiochemical and biological consideration in preparation of  nanoparticles 
The large number of molecule and manufacturing methods and  possibility 
to stabilize these particles by freeze drying has offered more advantage over the 
other colloidal carrier systems eg, liposomes. However, during preparation of the 
nanoparticles, the following factors should be taken into consideration. 
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Choice of materials and methods 
 It depends on the property of the drug which is associated with the 
nanoparticles carrier. Thus for hydrophobic drugs the continuous aqueous 
phase should be used for only for hydrophilic drug appear hydrophobic 
continuous phase should be used. 
 Natural macromolecules like proteins and cellulose are degradable base for 
the formulation of nanoparticles just like human serum albumin, bovine 
serum albumin, ethyl cellulose carrier and gelatin. 
 The opposite continuous phase increases absorption of drug to the 
nanoparticles remain in the body and it depends up on the material of 
which the carrier is made i.e., different degradation & elimination rates are 
obtained by using different materials & methods. 
 
ex:     Gelatin - very short periods of degradation and elimination 
           Albumin- medium fast degeneration and elimination 
            Long chain polycyanoacrylate–Long period for degradation and 
 elimination. 
             Poly methacrylate – Very long period of degradation and elimination. 
 Short persistent time carriers is intended when rapid elimination rate is 
 necessary to avoid accumulation. 
 Long persistence is necessary incase of vaccination. 
 
Release consideration 
There are two mechanisms commonly considered in explaining solute 
transport through a polymer matrix, they are 
a) Pore mechanisms  
b) Partition mechanisms. 
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Stability 
The drug released from nanoparticles in plain solvents may be rapid 
compared to some of the material used like polycyanoacrylate depolymorises in 
aqueous media. So nanoparticles should not be stored in aqueous media and in 
addition, all the types of nanoparticles can be freeze dried. 
Toxicity 
 Till now, there are very less results available on the toxicity of 
nanoparticles in blood and body distribution studies. No adverse reactions are 
reported. 
Structure  
According to Birren back nanoparticles are spherical in shape, they are 
non-toxic polymeric material with entrapped bioactive material. Particles diameter 
lies between 20-35µm. 
Polymers used in preparation of nanoparticles 
        The polymers should be compatible with the body, they should be (non-
toxicity) and (non- antigenicity) and they should be biodegradable and 
biocompatible. 
Natural polymers 
The most commonly employed natural polymers in preparation of  
polymeric nanoparticles are 
 Chitosan  
 Gelatin  
 Sodium alginate  
 Albumin  
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 Synthetic polymers 
 Polylactides (PLA) 
 Polyglycolides(PGA) 
 Poly(lactide co-glycolides) (PLGA)  
 Polyanhydrides 
 Polyorthoesters  
 Polycyanoacrylates 
 Polycaprolactone 
 Poly glutamic acid  
 Poly malic acid 
 Poly(N-vinyl pyrrolidone) 
 Poly(methyl methacrylate) 
 Poly(vinyl alcohol) 
 Poly(acrylic acid) 
 Poly acrylamide  
 Poly(ethylene glycol) 
 Poly(methacrylic acid (Nagavarma et al., 2012). 
Mechanisms of drug release  
The polymeric nanoparticales delivers the drug at the tissue site by any one 
of the 3 general physic chemical mechanisms. mainly by 
1. Swelling of the polymeric nanoparticles first by hydration followed by 
 release of drug through diffusion. 
2 An enzymatic reaction which results in either rupture or cleavage or 
degradation of the polymer at the delivery site, there by release of the drug 
from the entrapped inner core. 
3 Dissociation of the drug from the polymer or its de-adsorption/release 
 from the swelled nanoparticles (Nagavarma et al., 2012). 
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Classification of nanoparticles  
 There are many approaches for classification of nano materials. Nano 
particles can be classified based on  
 One dimensions 
 two dimensions 
 three dimensions 
One dimension nanoparticles 
 One dimensional system of classification includes thin film or 
manufactured surfaces and has been used for decades in electronics, chemistry and 
engineering. Production of thin films (sizes1-100 nm) or monolayer is now 
common in the field of solar cells or catalysis. This thin films are used in 
technological applications, like information storage systems, chemical and also 
biological sensors, fibre-optic systems, magneto-optic and optical device  
(Sovan et al., 2011). 
 
Two dimension nanoparticles  
Carbon nanotubes (CNTs) 
 Carbon nanotubes are hexagonal network of carbon atoms, they are 1 nm 
in diameter and 100 nm in length, in the form of layer of graphite rolled into 
cylinder. CNTs are of two types, single-walled carbon nanotubes (SWCNTs) and 
multi-walled carbon nanotubes (MWCNTs).The small dimensions of carbon 
nanotubes, combined with remarkable physical, mechanical and electrical 
properties, make them a unique materials. They show metallic or semi conductive 
properties, depending on how the carbon leaf is wound on itself. The density that 
nanotubes can be able to carry is extremely high and can reach even one billion 
amperes per square meter making it a superconductor. The mechanical strength is 
sixty times greater than the best steels. Carbon nanotubes have a great capacity for 
molecular absorption and offer a three dimensional configuration and they are 
chemically very stable (Sovan et al., 2011).  
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Three dimension nanoparticles 
Fullerenes (Carbon 60): 
 Fullerenes are spherical cages. They contain 28 to more than 100 carbon 
atoms. a hollow ball which is composed of interconnected carbon pentagons and 
hexagons, resembles a soccer ball. Fullerenes are class of materials having unique 
physical properties. They can be exposed to extreme pressure and it regain their 
original shape when the pressure is released. They do not combine with each other 
and used as lubricants. They have good electrical properties and it has been used 
them in the electronic field, like application ranging from data storage to 
production of solar cells. Fullerenes offer potential application in the area of nano 
electronics. therefore fullerenes are empty structures with dimensions which are 
similar to several biological active molecules (Sovan et al., 2011). 
Nano particles preparation 
 Nanoparticles are prepared from a variety of materials like proteins 
polysaccharides and synthetic polymers. The selection of matrix materials 
depends on many factors such as: 
 Size of nanoparticles needed 
 Inherent properties of the drug, like aqueous solubility and stability  
 Surface characteristics like charge and permeability 
 Degree of biodegradability, biocompatibility and toxicity 
 Drug release profile desired 
 Antigenic property of the final product 
Nanoparticles preparation is most frequently by three Methods 
1. From dispersion of preformed polymers 
2. By polymerization of monomers 
3. Ionic gelation or co-acervation of hydrophilic polymers (Nagavarma et al., 
 2012). 
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4. PREPARATION TECHNIQUES OF NANOPARTICLES 
       The selection of the appropriate method for the preparation of 
nanoparticles depends on the physicochemical characteristics of the polymer and 
the drug to be loaded. On the contrary, the preparation techniques largely 
determine the inner structure, in vitro release profile and the biological fate of 
these polymeric delivery systems (Kreuter et al., 1991). Two types of systems 
with different inner structures are apparently possible including: 
• A matrix type system consisting of an entanglement of oligomer or 
 polymer units (nanoparticles/nanospheres). 
• A reservoir type of system comprised of an oily core surrounded by an 
 embryonic polymeric shell (nanocapsules). 
 The drug can either be entrapped within the reservoir or the matrix or 
otherwise be adsorbed on the surface of these particulate system. The polymers 
are strictly structured to a nanometric size range particle(s) using appropriate 
methodologies. 
1. Amphiphilic macromolecule cross-linking 
 a. Heat cross-linking 
 b. Chemical cross-linking 
2.  Polymerization based methods 
 a.  Polymerization of monomers in situ 
 b. Emulsion (micellar) polymerization 
 c. Dispersion polymerization 
 d. Interfacial condensation polymerization  
 e. Interfacial complexation 
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Figure: 2  Nanoparticles/Nanospheres and Nanocapsules with the  
mode of drug entrapment 
3.  Polymer precipitation methods 
 a. Solvent extraction/evaporation 
 b. Solvent displacement (nanoprecipitation) 
 c. Salting out (Nagavarma et al., 2012) 
Polymers used for the Preparation of Nanoparticles and Nanocapsules 
Polymer use Technique Candidate drug 
Hydrophilic 
Albumin, gelatin 
 Heat denaturation and 
cross-linking in W/O 
emulsion Desolvation and 
cross-linking in aqueous 
medium 
Hydrophilic 
Alginate, chitosan 
Dextran 
Cross-linking in aqueous 
medium 
Polymer precipitation in an 
organic solvent 
Hydrophilic and protein 
affinity 
Hydrophobic 
Hydrophobic 
Poly( alky Icy 
anoacrylates) 
Emulsion polymerization 
Interfacial O/W 
polymerization 
Hydrophilic 
hydrophobic 
Polyesters Poly(lactic 
acid), Poly(lactide- 
co-glycolide), poly 
(e-caprolactone) 
Solvent extraction-
evaporation 
Solvent displacement 
Salting out 
Hydrophilic & hydrophobic 
Soluble in polar solvent 
Soluble in polar solvent 
                 Targeted and controlled drug delivery by( Khar et al., 2006) 
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Solvent evaporation method 
  In this method, the polymer is dissolved in a organic solvent like  
dichloromethane, chloroform or ethyl acetate, and  also used as the solvent in 
dissolving the hydrophobic drug. The mixture of polymer and drug solution is 
emulsified in an aqueous solution that contain a surfactant or emulsifying agent to 
form oil in water (o/w) emulsion. After stable emulsion is formed, the organic 
solvent is evaporated by reducing the pressure or by continuous stirring. Particle 
size is influenced by the type and concentrations of stabilizer, homogenizer speed 
and polymer concentration. To produce small particle size, often a high speed 
homogenization or ultra sonication is used (Nagavarma et al., 2012). 
 
 
 
 
 
                             
Figure : 3 Solvent evaporation method 
Nano precipitation method 
         Nano precipitation also called solvent displacement method involves the 
precipitation of a preformed polymer from an organic solution and also the 
diffusion of the organic solvent in the aqueous medium in the presence or absence 
of a surfactant. The polymer generally PLA, is dissolved in water-miscible solvent 
having intermediate polarity, which leads to the precipitation of nanospheres. This 
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phase is then injected into a stirred aqueous solution which contains a stabilizer as 
a surfactant. Polymer deposited on the interface between the water and the organic 
solvent, caused due to fast diffusion of the solvent, leads to the formation of a 
colloidal suspension. 
 To facilitate formation of colloidal polymer particles in the first step of the 
procedure, phase separation is done with a totally miscible solvent which is also a 
non solvent of the polymer (Nagavarma et al., 2012). 
                
 
 
 
 
 
Figure : 4  Nano precipitation method 
Solvent Displacement / Precipitation method 
             Solvent displacement method involves the precipitation of a preformed 
polymer from an organic solution and the diffusion of the organic solvent in the 
aqueous medium either in the presence or absence of surfactant. Polymers, drug, 
and or lipophilic surfactant are dissolved in a semi- polar water miscible solvent 
such as acetone or ethanol. Then the solution is poured or injected into an aqueous 
solution containing stabilizer with magnetic stirring. Nano particles are formed 
instantaneously by the rapid solvent diffusion. 
 
Introduction 
 
 
Department of Pharmaceutics  14 
Then the solvent is removed from the suspensions under reduced pressure. 
The addition rate of the organic phase into the aqueous phase affect the size of 
particle, it was observed that a decrease in both particles size and drug entrapment 
occurs when the rate of mixing of the two phase increases. This method is well 
suited mostly for poorly soluble drugs. Nanosphere size, drug release and yield is 
effectively controlled by adjusting preparation parameters. Adjusting polymer 
concentration in the organic phase is found to be useful in the preparation of 
smaller size nanospheres which is restricted to a limited range of the polymer to 
drug ratio (Sovan et al., 2011). 
Emulsification/solvent diffusion method 
It is Modified version of solvent evaporation method in which The 
encapsulating polymer is made to dissolve in a partially water soluble solvent like 
propylene carbonate and is saturate with water to confirm the initial 
thermodynamic equilibrium of both the liquids. To produce the precipitation of 
the polymer and the formation of nanoparticles, it is important to promote the 
diffusion of the solvent of dispersed phase by diluting with an excess of water 
when the organic solvent is partly miscible with water or either with another 
organic solvent in the opposite case. Subsequently, the polymer-water saturated 
solvent phase is made emulsified in an aqueous solution containing stabilizer, 
leading to solvent diffusion of the external phase and leads to the formation of 
nanospheres or nanocapsules, based on the oil-to-polymer ratio. At last, the 
solvent is eliminated by evaporation or filtration, based on its boiling point 
(Nagavarma et al., 2012). 
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                               Figure: 5 Emulsification / solvent diffusion method 
Salting out method 
Salting out is the separation of a water miscible solvent from aqueous 
solution through a salting out effect. This procedure is considered as a 
modification of the emulsification/solvent diffusion. Polymer and drug are first 
dissolved in a solvent such as acetone, which is then emulsified into an aqueous 
gel containing the salting-out agent (electrolytes, such as magnesium chloride, 
calcium chloride, and magnesium acetate, or non- electrolytes such as sucrose) 
and also a colloidal stabilizer such as poly vinyl pyrolidone or hydroxyl ethyl 
cellulose. This oil/water emulsion is then diluted with a sufficient volume of water 
or aqueous solution to enhance the diffusion of acetone into the aqueous phase, 
thus induces the formation of nanospheres (Nagavarma et al., 2012). 
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Figure:6  Salting out method 
Dialysis 
Dialysis is a simple, effective method for the preparation of small, narrow-
distributed PN. Polymer is first dissolved in an organic solvent and  
then placed inside a dialysis tube with molecular weight cut off. Dialysis is 
performed against a non-solvent miscible with former miscible. The displacement 
of the solvent inside is followed by the aggregation of polymer due to a loss of  
solubility and homogeneous suspensions of nanoparticles formed  
(Nagavarma et al., 2012). 
Polymerization method 
In this, monomers are polymerized to give nanoparticle in aqueous 
solution. Drug is incorporated by dissolving in the polymerization medium or 
either by adsorption on to the nanoparticles after polymerization is completed. The 
nanoparticle suspension is later purified to remove stabilizers and surfactants 
employed in polymerization by ultracentrifugation and re-suspending  
the particles in an isotonic surfactant-free medium. This technique is  
for making polybutylcyanoacrylate or poly (alkyl cyanoacrylate) nanoparticles 
(Nagavarma et al., 2012). 
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Emulsion polymerization 
Emulsion polymerization and development of many polymer materials 
have recently increased. A typical formulation used in mini-emulsion 
polymerization comprises of water, monomer mixture, co-stabilizer, surfactant, 
and a initiator. The emulsion polymerization differs from mini-emulsion 
polymerization in the use of a low molecular mass compound as co-stabilizer and 
also in the use of a high-shearing device (ultrasound etc). Mini-emulsions are 
stabilized, and requires high-shear to get a steady state, they have an interfacial 
tension much greater than zero 31. The polymer nanoparticles are prepared by 
using Mini-emulsion method only (Nagavarma et al., 2012). 
Micro-emulsion polymerization 
Micro-emulsion polymerization is a new approach for making nano sized 
polymer particles and has gained significant attention. Emulsion and micro-
emulsion polymerization appear similar because both methods produces colloidal 
polymer particles of high molar mass, but they are entirely different kinetics. 
Particle size and the average number of chains per particle is small in micro-
emulsion polymerization. In micro-emulsion polymerization, an initiator, which is 
water-soluble, is being added to the aqueous phase of a thermodynamically stable 
micro-emulsion that contains swollen micelles. The polymerization starts from 
this thermodynamically stable, spontaneously formed state and depends on high 
quantities of surfactant systems, which has an interfacial tension at the oil/water 
interface close to zero (Nagavarma et al., 2012). 
Interfacial polymerization 
It is one of the well-established methods for preparation of polymer 
nanoparticles. It involves step polymerization of two reactive monomers or agents, 
which is dissolved in two phases respectively (i.e., continuous-and dispersed-
phase), the reaction takes place at the interface of the two liquids. Nanometer-size 
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hollow polymer particles are synthesized by interfacial cross-linking reactions like 
poly addition or poly condensation or radical polymerization. Oil-containing 
nanocapsules are obtained by polymerization of monomers at oil/water interface 
of fine oil-in water micro-emulsion. The organic solvent, which s completely 
miscible with water is serving as a monomer vehicle and interfacial 
polymerization of the monomer may occur at the surface of the oil droplets that is 
formed during emulsification. To enhance nanocapsule formation, aprotic 
solvents, such as acetone and acetonitrile is used.  Protic solvents, like ethanol, n-
butanol and isopropanol, is found to enhance the formation of nanospheres with 
nanocapsules (Nagavarma et al., 2012). 
Control living/radical polymerization 
Radical polymerization include the lack of control in the molar mass, the 
molar mass distribution, the end functionalities and the macromolecular 
architecture. The limitations are due to the unavoidable fast radical–radical 
termination reactions. The recent emergence of many Controlled or ‘Living’ 
Radical Polymerization (C/LRP) processes has opened a new area by involvement 
of an old polymerization technique. The factors that contributes to this trend of the 
C/LRP process is increased environmental concern and also a sharp  
growth of pharmaceutical and medical applications for hydrophilic polymers 
(Nagavarma et al., 2012).  
Co-acervation or ionic gelation method 
The nanoparticles is prepared by using biodegradable hydrophilic  
polymers like chitosan, gelatin and sodium alginate. A method for preparing 
hydrophilic chitosan nanoparticles by ionic gelation is developed. In this method,  
positively charged amino-group of chitosan interact with negative charged 
tripolyphosphate to form co acervates with a size which is in the range of 
nanometer (Nagavarma et al., 2012). 
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Figure: 7 Co-acervation or ionic gelation method 
 
Production of nanoparticles using supercritical fluid technology 
Figure 7 : Co-acervation or ionic gelation method 
Conventional methods such as solvent extraction-evaporation, solvent 
diffusion and organic phase separation methods needs the use of organic solvents 
which is hazardous to the environment and to physiological systems. Hence, the 
supercritical fluid technology is an alternative to produce biodegradable micro-
and nanoparticles just because supercritical fluids are found to be environmentally 
safe. A supercritical fluid is defined as a solvent at a temperature above its critical 
temperature, in which the fluid remains as a single phase regardless of pressure. 
Supercritical CO2 (SC CO2) is widely used supercritical fluid because of the mild 
critical conditions (Tc = 31.1°C, Pc = 73.8 bars), nontoxicity, non flammability 
and low price. The common processing techniques for supercritical fluids are 
Supercritical Anti-Solvent (SAS) and Rapid Expansion of Critical Solution 
(RECS). 
The process of SAS involves liquid solvent, eg methanol, that is 
completely miscible with the supercritical fluid (SC CO2), mainly to dissolve the 
solute which is to be micronized; at the process conditions, because the solute is 
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not soluble in supercritical fluid, the extract of solvent by supercritical fluid leads 
to formation of precipitation of the solute, which results in the formation of 
nanoparticles. RECS differs from that of the SAS process. In that, solute is 
dissolved in a supercritical fluid (such as supercritical methanol) and then the 
solution is made to rapidly expand through a small nozzle in a region lower 
pressure, As a result the solvent power of supercritical fluids decreases and the 
solute eventually precipitates out (Nagavarma et al., 2012). 
Drug may be incorporated into nanoparticles by any one of the following 
ways 
 By preparing a solution of drug in the polymer. 
 By solid dispersion of the drug in the polymer. 
 By the surface adsorption of the drug. 
 By chemically binding of the drug to the polymer 
Modification of nanoparticles which alter the drug release rate 
 Nanoparticles coated with plasma proteins creates a significant additional            
 diffusion barrier which retards the drug release. 
 Direct contact of nanoparticles with biological or artificial membrane 
 enhances drug delivery to these membranes in comparison to simple 
 solutions. 
 
  
Introduction 
 
 
Department of Pharmaceutics  21 
NANOPARTICLES CHARACTERIZATION 
Measurement of particle size and zeta Potential 
                Photon Correlation Spectroscopy (PCS) and Laser Diffraction (LD) are 
the most powerful techniques for measurements of particle size. PCS also known 
as dynamic light scattering measures the fluctuation of the intensity of the 
scattered light which is caused by particle movement. This method covers a size 
range from a few nanometers to about 3 microns. PCS is a good tool for 
characterize nanoparticles, but it is not able to detect larger micro particles. The 
physical stability of optimized SLN dispersed is generally more than 12 months. 
ZP measurements allow predictions about the storage stability of colloidal 
dispersion (Kumar et al., 2014). 
Particle size 
Particle size distribution and morphology are the most important 
parameters of characterization of nanoparticles. Morphology and size are 
measured by electron microscopy. The major application of nanoparticles is in 
drug release and drug targeting. It has been found that particle size affects the 
drug release. Smaller particles offer larger surface area. As a result, most of the 
drug loaded onto them will be exposed to the particle surface leading to fast drug 
release. On the contrary, drugs slowly diffuse inside larger particles. As a 
drawback, smaller particles tend to aggregate during storage and transportation of 
nanoparticles dispersion. Hence, there is a compromise between a small size and 
maximum stability of nanoparticles. Polymer degradation can also be affected by 
the particle size. For instance, the degradation rate of poly (lactic-co-glycolic acid) 
was found to increase with increasing particle size in vitro (Kumar et al., 2014). 
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Scanning Electron microscopy 
 Scanning Electron Microscopy (SEM) is giving morphological 
examination with direct visualization. The techniques based on electron 
microscopy offer several advantages in morphological and sizing analysis; 
however, they provide limited information about the size distribution and true 
population average. For SEM characterization, nanoparticles solution should be 
first converted into a dry powder, which is then mounted on a sample holder 
followed by coating with a conductive metal, such as gold, using a sputter coater. 
The sample is then scanned with a focused fine beam of electrons. The surface 
characteristics of the sample are obtained from the secondary electrons emitted 
from the sample surface. The nanoparticles must be able to withstand vacuum, and 
the electron beam can damage the polymer. The mean size obtained by SEM is 
comparable with results obtained by dynamic light scattering. Moreover, these 
techniques are time consuming, costly and frequently need complementary 
information about sizing distribution (Kumar et al., 2014). 
Determination of Entrapment Efficiency (EE)  
The EE was determined by analyzing the free drug content in the 
supernatant obtained after centrifuging the Nanoparticles suspension in high speed 
centrifuge at 15000 rpm for 30 min using Remi centrifuge (Mumbai, India). The 
EE was calculated as follows: (Havanoor et al., 2014). 
𝐸݊𝑡𝑟𝑎𝑝݉݁݊𝑡 𝐸݂݂𝑖𝑐𝑖݁݊𝑐𝑦  = 100Pr X
ContentDruglTheoritica
ContentDrugactical
 
Drug release kinetics  
Different kinetic models such as zero order (cumulative amount of drug 
released vs time), first order (log cumulative percentage of drug remaining vs 
time), Higuchi model (cumulative percentage of drug released vs. square root of 
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time), Korsmeyer-Peppas model were applied to interpret the drug release  
kinetics from the formulations. The best‐fit model was decided based on the  
highest regression values (r2) of obtained release data of formulations 
 (Balaiah et al., 2012). 
Infrared spectroscopy (IR) 
             Shimadzu IR-470 spectrometer was used to record the IR spectrum of  
nanoparticles from 400 to 4000 cm-1. The sample was grounded with Potassium 
Bromide (KBr) and pressed to a suitable size disk for measurement. 
 
In vitro drug release  
 The In vitro drug release profile of the prepared Imatinib Mesylate 
nanoparticles were investigated by USP Type I dissolution apparatus in using 
distilled water as dissolution medium. At a temperature of 37°C±2°C and the 
stirrer was rotated at 50 rpm speed. Nanoparticles containing Imatinib Mesylate 
equivalent 250 mg is introduced into the basket and involved in the dissolution 
medium transferred into the vessel containing 900 ml of purified water. 
 At specific intervals, 1 ml aliquot of the dissolution medium was sampled 
(the pooled sample was replaced with a fresh purified water), filtered by 
whatmann filter paper (pore size: 0.45 pm) and determine the amount of drug 
from UV absorbance of the sample solution, in comparison with a standard 
solution having a known concentration of raw drug. (Mansouri et al., 2011) 
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LITERATURE REVIEW 
 Kassem et al., (2017) This research purposed to formulate an optimized 
imatinib mesylate (IM) loaded nanoparticles to improve its chemotherapeutic 
efficacy. The influence of 3 formulation factors on  size (Y1), zeta potential (Y2), 
entrapment capacity percentage (Y3), the percentage of initial drug release after 2 
h (Y4) and the percentage of cumulative drug release after 24 h (Y5) were studied 
and optimized using Box-Behnken design. Optimum desirability was specified 
and the optimized formula was prepared, stability tested, morphologically 
examined, checked for vesicular bilayer formation and evaluated for its in vitro 
cytotoxicity on 3 different cancer cell lines namely MCF-7, HCT-116, and HepG-
2 in addition to1 normal cell line to ensure its selectivity against cancer cells. The 
actual responses of the optimized IM formulation were 425.36 nm, _62.4 mV, 
82.96%, 18.93%, and 89.45% for Y1, Y2, Y3, Y4, and Y5, respectively. 
 
 Snehalatha et al., (2016) investigated Etoposide-loaded  were prepared 
using nanoprecipitation and emulsion solvent evaporation techniques using -co-
glycolic acid and poly(ε-caprolactone) in presenceof Pluronic F68, respectively. 
Effect of formulation variables like stabilizer concentration, amount of polymer, 
and drug was studied. These parameters were found to affect particle size, zeta 
potential, drug content, and entrapment efficiency of nanoparticles. The methods 
produced nanoparticles with good entrapment efficiency of around 80%. Recovery 
of nanoparticles was as high as 95% and drug content was around 1.5%. Increase  
in lactide content decreased the release of etoposide in vitro and  
poly(ε- caprolactone) nanoparticles retarded etoposide release for 48 hr. The 
results show the suitability of polylactide-co-glycolic acid and poly(ε-
caprolactone) nanoparticles as potential carriers for controlled delivery of 
etoposide. 
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 Alexis et al., (2016) investigated nanoparticles as drug delivery systems 
enable unique approaches for cancer treatment. Over the last two decades, a large 
number of nanoparticle delivery systems have been developed for cancer therapy, 
including organic and inorganic materials. Many liposomal, polymer–drug 
conjugates, and micellar formulations are part of the state of the art in the clinics, 
and an even greater number of nanoparticle platforms are currently in the 
preclinical stages of development. More recently developed nanoparticles are 
demonstrating the potential sophistication of these delivery systems by 
incorporating multifunctional capabilities and targeting strategies in an effort to 
increase the efficacy of these systems against the most difficult cancer challenges, 
including drug resistance and metastatic disease. Here, we will review the 
available preclinical and clinical nanoparticle technology platforms and their 
impact for cancer therapy. 
 
 Kalepua et al., (2015) investigated The emerging trends in the 
combinatorial chemistry and drug design have led to the development of drug 
candidates with greater lipophilicity, high molecular weight and poor water 
solubility.One of largest-selling anticancer drugs Imatinib is marketed as a salt 
form, Imatinib mesylate .The drug exhibits poor solubility and hence mesylate salt 
was used for its development, which is soluble in wate at pH<5.5. Among the two 
polymorphic forms (α and β), generated by Imatinib salt, the β forms more stable 
with acceptable pharmaceutical properties. However, additional marketing rights 
were assigned to the innovator due to their patent protection of the β form. 
Over the past two decades, nanoparticle technology has become a well-
established and proven formulation approach for poorly-soluble drugs. Reducing a 
drug's particle size to sub-micron range is referred to as ‘nanonization’. In the 
field of pharmaceuticals, the term ‘nanoparticle’ is applied to structures less than 
1 ȝm in size. 
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 Jeena et al., (2015) carried out the antitumor and cytotoxic activity of 
ginger essential oil (zingiber officinale roscoe). GEO showed potent in vitro 
cytotoxic activity against DLA and EAC cell lines. IC50 value for DLA cell line 
was 11 ȝg/ml and for EAC cell lines 18 ȝg/ml. The IC50 of GEO was found to be 
41 ȝg/ml against the L929 cell mg/kg and 1000 mg/kg body weight) significantly 
reduced the volume of solid tumor development by 54.4% and 62.4% 
respectively. The life span was increased up to 50% in 1000 mg/kg b. wt GEO 
treated ascites tumor induced animals 
 Fitzgibbon et al., (2015) investigated clinical outcome of surgical 
revascularization using autologous vein graft is limited by vein graft failure 
attributable to neointima formation. Platelet-derived growth factor (PDGF) plays a 
central role in the pathogenesis of vein graft failure. Therefore, we hypothesized 
that nanoparticle (NP)-mediated drug delivery system of PDGF-receptor (PDGF-
R) tyrosine kinase inhibitor (imatinib mesylate: STI571) could be an innovative 
therapeutic strategy. Uptake of STI571-NP normalized PDGF-induced cell 
proliferation and migration. Excised rabbit jugular vein was treated ex vivo with 
PBS, STI571 only, FITC-NP, or STI571-NP, then interposed back into the carotid 
artery position. NP was detected in many cells in the neointima and media at 7 and 
28 days after grafting. Significant neointima was formed 28 days after grafting in 
the PBS group; this neointima formation was suppressed in the STI571-NP group. 
STI571-NP treatment inhibited cell proliferation and phosphorylation of the 
PDGF-R-β but did not affect inflammation and endothelial regeneration. STI571-
NP-induced suppression of vein graft neointima formation holds promise as a 
strategy for preventing vein graft failure. 
 
   Mehrotra et al., (2015) developed the incorporation of lomustine, a 
hydrophobic anticancer drug into PLGA nanoparticles by interfacial deposition 
method was optimized. Based on the optimal parameters, it was found that 
lomustine-PLGA nanoparticles with acceptable properties could be obtained. 
Optimization of formulation variables to control the size and drug entrapment 
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efficiency of the prepared nanoparticles seems to be based on the same scientific 
principles as drug-loaded nanoparticles prepared by nanoprecipitation, solvent 
evaporation method. The process was the most important factor to control the 
particle size, while both the drug-polymer interaction and the partition  of drug in 
organic and aqueous phases were the crucial factors to govern the drug entrapment 
efficiency and biodistribution profiles of prepared nanoparticles in albino mice 
showed higher plasma drug concentration for longer period of time, elevated drug 
concentration in lungs and slow elimination from kidney. No toxic effects of 
prepared nanoparticles were observed in histopathological examination of lungs 
and kidney. The systematic investigation reported here promises the development 
of PLGA nanoparticles loaded with lomustine when tested in Lung Cancer cell 
line L132 and toxicological/ histopathological studies in albino mice. 
 
 Jana et al., (2014) Prepared Felodipine nanoparticles using poly (D, L-
lactic-co-glycolic acid) were prepared by single emulsion solvent evaporation 
technique and the physico-chemical characterization of prepared nanoparticles 
confirmed the particles were nanosize range with smooth and spherical 
morphology. Further, the compatibility of drug-polymer combination was 
analyzed by FTIR and DSC study. The in vitro drug release study of PLGA 
nanoparticles showed longer duration of drug release with reduced burst release 
compared with pure felodipine. The in vitro drug release data were fitted with 
various mathematical models to establish the drug release mechanism from the 
nanoparticles and found to follow mixed order kinetics. 
 
 Akagi et.al (2014) Platelet–derived growth factor (PDGF) is implicated in 
the pathogenesis of pulmonary arterial hypertension (PAH). Imatinib, a PDGF-
receptor tyrosine kinase inhibitor, improved  hemodynamics, but serious side 
effects and drug discontinuation are common when treating PAH. A drug delivery 
system using nanoparticles (NPs) enables the reduction of side effects while 
maintaining the effects of the drug. We examined the efficacy of imatinib-
incorporated NPs (Ima-NPs) in a rat model and in human PAH-pulmonary arterial 
Literature Review 
 
 
 
Department of Pharmaceutics  28 
smooth muscle cells (PASMCs). Ima-NPs significantly inhibited proliferation 
after 24 hours of treatment. Ima-NPs significantly inhibited proliferation Delivery 
of Ima-NPs into lungs suppressed the development of MCT-induced PAH by 
sustained antiproliferative effects on PASMCs. 
 Bingwang et al (2014) developed the combination of chemotherapeutic 
agents with different pharmacological action has emerged as promising 
therapeutic strategy in the treatment of cancer. The antitumor activity of paclitaxel 
and etoposide loaded PLGA nanoparticles for the treatment of osteosarcoma. The 
resulting drug loaded PLGA NP exhibited a nanosized dimension with uniform 
spherical morphology. The NP exhibited a sustained release profile for both PTX 
and ETP throughout the study period without any sign of initial burst release. The 
combinational drug loaded PLGA NP enhanced cytotoxic effect in MG63 and 
saos-2 osteosarcoma cell lines. The greater inhibitory effect of nanoparticle 
combination would be of greater advantage during systemic cancer therapy. 
 
 Ruma Maji et.al (2014) Four formulations o Tamoxifen citrate loaded 
plylactide-co-glycolide(PLGA)based nanoparticles(TNPs)were developed and 
chracterised.Their internalizatin by Michigan Cancer Foundation-7(MCF-7)breast 
cancer cells was also investigated.Nanoparticles were prepared by a multiple 
emulsion solvent evapouration method.Then the  following studies were carried 
out:drug- excipients interaction studies using Fourier transform infrared 
spectroscopy(FTIR),surface morphology by  filed emission scanning electron 
microscopy(FESEM),zeta potential and size ditribution using Zetasizer NanoZS90 
and particle size analyzer and in vitro drug release.Invitro cellulr uptake of 
nanoparticles  were assessed by confocal microscopy and their cell viability  
was studied and drug loaded nanoprticle were found to be moe cytotoxic than the 
free drug. 
 
 Yass et al., (2014) Prepared Sildenafil Citrate (SFC) nanoparticles using  
melt method was employed for preparing SFC – solid lipid microparticles 
dispersions (SFC – SLMDs), a non – solvent technique aid in the production of 
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drug – matrix dispersions with sustained release properties. Glyceryl behenate 
(GB) (Compritol® 888 ATO) was used as the retarding matrix and the results 
shown that as its ratio increase there was a decrease in the fine particle fraction, an 
increase in the drug content and a prolong drug release pattern. The best model fit 
the release data was Higuchi – Matrix model which indicates drug diffusion – 
controlled releasing mechanism. Thus, inhaled SFC – SLMDs dry powder will 
improve PAH treatment via drug localization at low doses and reducing the 
administration frequency. 
 
 
 Kumar et al., (2014) developed Formulation and evaluation of 
nanoparticles containing artemisinin HCL is poorly soluble in water and a fast-
acting blood schizonticide effective in treating the acute attack of malaria 
(including chloroquine – resistant and celebral malaria). Artemisinin are effective 
against multi-resistant strains of P. falciparum. The purpose of the present work is 
to minimize the dosing frequency, taste masking and toxicity and to improve the 
therapeutic efficacy by formulating Artemisinin HCl nanoparticles. Artemisinin 
HCl nanoparticles were formulated by solvent evaporation method using polymer 
poly(ε-caprolactone) with five different formulations. Nanoparticles were 
characterized by determining its particle size, polydispersity index, drug 
entrapment efficiency, particle morphological character and drug release. The 
particle size ranged between 100nm to 240nm. Drug entrapment efficacy was > 
99%. The in-vitro release of nanoparticles were carried out which exhibited a 
sustained release of Artemisinin HCl from nanoparticles up to 24hrs. The results 
showed that nanoparticles can be a promising drug delivery system for sustained 
release of Artemisinin HCl. 
 
 Kotikalapudi et al., (2014) investigated Prepared and Evaluated  
Domperidone loaded solid lipid nanoparticles (DOM-SLN). DOM loaded SLN 
were prepared by hot homogenization followed by ultrasonication technique. 
DOM- SLN were characterized for particle size, polydispersity index (PDI), zeta 
potential and entrapment efficiency and in vitro drug release behaviour were 
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investigated. P-XRD and DSC analysis were performed to characterize the state of 
drug and lipid modification. Shape and surface morphology were determined by 
transmission electron microscopy (TEM). SLN formulations were subjected to 
stability study over a period of 30 days. The mean particle size, PDI, Zeta 
potential and entrapment efficiency of optimized SLN were found to be 56 nm, 
0.154, 34 mV,98.5 %. P-XRD and DSC studies revealed that DOM was in an 
amorphous state. Shape and surface morphology was determined by TEM 
revealed fairly spherical shape of nanoparticles.  
 
 Bharti et al., (2014) Formulation and evaluation of gelatin nanoparticles 
for pulmonary drug delivery entrapment efficiency of all gelatin nanoparticles 
formulations were found to be in the range of 46.16 % - 58.60 %. The particle size 
of gelatin nanoparticle formulations(GNps1, GNps2, GNps3, GNps4) were found 
to be 179.9 nm, 198.4 nm, 252.4 nm and 1545 nm, respectively. The gelatin 
nanoparticle formulation GNps3 was selected best formulation depending upon 
the particle size less then 500nm and higher entrapment efficiency as compared to 
GNps1 and GNps2. The zeta potential of gelatin nanoparticles found to exhibit 
stability due to positive charge on the surface. The transmission electron 
microscopy indicated the spherical surface of the gelatin nanoparticles. The in 
vitro release was found to follow higuchi plot as compared to zero order plot, first 
order plot and krosmeyer peppas plot. Stability studies showed that gelatin 
nanoparticle formulation GNps3 was stable when tested for particle size, 
entrapment efficiency and in vitro drug release at refrigerated condition (5º±3ºC), 
at room temperature (25º±2ºC/65%±5% RH) and at accelerated condition 
(40º±2ºC/75%±5% RH) according to ICH guidelines for 6 months(180 days). 
 
      Parvin et al., (2014) Formulated  Dexamethasone  solid lipid  nano  particles 
with stearic acid as solid lipid, lutrol F-68 as surfactant and tween-80 as stabilizer. 
SLNPs are prepared by hot homogenzation method at different ratio of drug, lipid, 
surfactant and stabilizer and designated as DNP1 to DNP6. In vitro dissolution 
study was performed using the USP type II apparatus (paddle method) at 50 rpm 
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to a temperature of 37°±0.5°C in distilled water containing 0.75% 
w/vSLS(sodium lauryl sulfate). The absorbance of sample was measured 
spectrophotometrically at Ȝmax 239nm on a UV-Visible spectrophotometer. 
Release pattern of drug was found to follow zero order, first order and Korsmeyer-
Peppasequations.  Pure drug showed only 27.25% release in 50 min whereas the 
dexamethasone SLNPs showed faster (66.19%) in vitro drug release.  
    
   Thavamani et al., (2014) investigated the Anticancer activity of 
cissampelos pareira against dalton’s lymphoma ascites bearing mice. Methanol 
Extract of Cissampelos pariera (MECP)  showed a potent cytotoxic activity, with 
an IC 50 value of 95.5 ȝg/ml and a significant (p < 0.001) decrease in packed cell 
volume, viable cell count, and an increased lifespan (54 and 72%). The 
hematological and serum biochemical profiles were restored to normal levels in 
MECP-treated mice. The MECP-treated group significantly (p < 0.001) decreased 
SOD, lipid peroxidation, and CAT to normal. 
 
 Firdhouse et al., (2013) evaluated the biosynthesis of silver nanoparticles 
using the extract of Alternanthera sessilis - antiproliferative effect against prostate 
cancer cells. The biosynthesis of silver nanoparticles using the extract of 
Alternanthera sessilis was economical, non-toxic, and environmentally benign. 
The synthesized silver nanoparticles were stable due to the reducing and capping 
nature of phytoconstituents present in the aqueous extract of Alternanthera sessilis 
analyzed by FTIR spectra. The particle size of the synthesized silver nanoparticles 
is less than 50 nm which was confirmed by XRD and SEM analysis. Nanosilver 
shows good cytotoxic activity against prostate cancer cells and may serve as a 
potential anticancer drug for cancer therapy. 
       
     Karal-Yilmaz et al., (2012) Poly(lactic-co-glycolic acid) nanoparticles 
loaded with imatinib mesylate has been developed as a new therapeutic strategy to 
prevent craniopharyngioma recurrence. Nanoparticles composed of different 
lactic/glycolic acid ratios, molecular weights and drug compositions were 
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synthesized and loaded with imatinib mesylate by modified double-
emulsion/solvent evaporation technique and subsequently characterized by 
particle-size distribution, scanning electron microscopy, encapsulation efficiency 
and in vitro drug release. Inhibitory potential of imatinib containing 
nanaoparticles on tumor neovascularization was investigated on 
craniopharyngioma tumor samples by rat cornea angiogenesis assay. Results 
showed that nanoparticles in different LA:GA ratios [LA:GA 50:50 (G50), 75:25 
(G25), 85:15 (G15)] considerably reduced neovascularization induced by 
recurrent tumor samples in an in vivo angiogenesis assay. 
. 
 Yin et al., (2012) Percutaneous coronary intervention (PCI) has become 
the most common revascularization procedure for coronary artery disease. The use 
of stents has reduced the rate of restenosis by preventing elastic recoil and 
negative remodeling. However, in-stent restenosis remains one of the major 
drawbacks of this procedure. Drug-eluting stents (DESs) have proven to be 
effective in reducing the risk of late restenosis, but the use of currently marketed 
DESs presents safety concerns, including the non-specificity of therapeutics, 
incomplete endothelialization leading to late thrombosis, the need for long-term 
anti-platelet agents, the use of DESs, and progress in nanoparticle drug- or gene-
eluting stents for the prevention and treatment of coronary restenosis. 
 
 Naik J P et al.,(2012) Formulated and optimized Repaglinide (Rg) loaded 
Eudragit RL-100 nanoparticles using Eudragit RL-100 nanoparticles have been 
developed by High Pressure Homogenizer Emulsification (HPHE) -Solvent 
Evaporation method indifferent ratios. The method was optimized using design of 
experiments by employing a 3-factor, 3-level Design Expert (version 8.0.7.1) 
Statistical Design Software and was subjected to various studies for 
characterization including Transmission electron microscopy (TEM), X-ray 
diffraction (XRD), Encapsulation efficiency (%EE), Particle Size Analysis (PSA) 
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etc. These studies are favorably revealed that the mean particle diameter of 
optimized formulation was 50 nm with crystalline nature. Moreover, formulated 
nanoparticles were also subjected to Fourier Transform Infrared Spectroscopy 
(FT-IR), Differential Scanning Calorimetry (DSC) for interaction between drug 
and polymer. The results were positive and showed that, there were no interaction 
between drug and polymer.  
 
 Kulathuran Pillai et al., (2012) discussed the antitumor activity of 
ethanolic extract of CNIDOSCOLUS CHAYAMANSA MCVAUGH against 
Dalton’s ascetic Lymphoma in mice.  Both doses of EECC decreased average 
increase in body weight, reduced the packed cell volume (PCV) viable tumor cell 
count and increased the life span of DAL treated mice and brought back the 
hematological parameters, serum enzyme and lipid profile near to normal values. 
All the values were found to be statistically significant with control group at 
p<0.001.These observations are suggestive of the protective effect of extracts in 
the Dalton’s Ascitic Lymphoma (DLA). 
 
 Masuda et.al (2011) The use of currently marketed drug eluting 
stents(DES) present safety concerns, including an increased risk of late 
thrombosis in the range of 0.6% per year in patients, including acute  coronary 
syndrome, which is thought to result from delayed endothelial healing effects. A 
new DES system targeting vascular smooth muscle cells without adverse effects 
on endothelial cells is therefore needed. Platelet derived growth factors (PDGF)  
plays a central role in the pathogenes of restenosis; therefore we hypothesised that 
Imatinib mesylate (PDGF receptor tyrosine kinase inhibitor) encapsulated 
bioabsorble polymeric nanoparticles(NP)-eluting stents attenuates in-stent  
neointima formation. 
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Imatinib NP attenuated the proliferation of vascular smooth muscle 
associated with inhibition of target molecule (phosphorylation of PDGF receptor-
β), but showed no effect on endothelial proliferation. 
 Junjie Zou et al., (2011) investigated Poly (lactic-co-glycolic acid) 
(PLGA) NPs containing rapamycin was prepared using an oil/water solvent 
evaporation technique. Nanoparticle size and morphology were determined by 
dynamic light scattering methodology and electron microscopy. In vitro 
cytotoxicity of blank, rapamycin-loaded PLGA (RPLGA) NPs was studied using 
MTT Assay. Rapamycin was efficiently loaded in PLGA nanoparticles with an 
encapsulation efficiency was 87.6. Thus concluded that sustained-release 
rapamycin from rapaymycin loaded NPs inhibits vein graft thickening without 
affecting the reendothelialization in rat carotid vein-to-artery interposition grafts 
 Sriram et al., (2010) discussed the Antitumor activity of silver 
nanoparticles in Dalton’s lymphoma ascites tumor model. Transmission Electron 
Microscope (TEM) showed that the purified nanoparticles were spherical with a 
mean diameter of 50 nm and the endotoxin assay revealed that the purified AgNPs 
were endotoxin-free. The AgNPs were found to be cytotoxic to tumor cells at 
concentrations of 500 nm and higher AgNPs at 500 nm decreased the viability of 
DLA cells to 50% of the initial level, and this was chosen as the IC50. The present 
study explores the potential antitumor activity of biologically synthesized AgNP 
in a DLA tumor system in vitro by activation of the caspase 3 enzyme. 
Histopathologic analysis of ascitic fluid showed a reduction in DLA cell count in 
tumor-bearing mice treated with AgNPs. These findings confirm the antitumor 
properties of AgNPs, and suggest that they may be a cost-effective alternative in 
the treatment of cancer and angiogenesis-related disorders. 
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  Nesalin et al., (2009) formulated and evaluated nanoparticles containing 
flutamide. Nanoparticles of Flutamide were formulated using chitosan polymer by 
ionic gelation technique. Nanoparticles of different core: coat ratio were 
formulated and analyzed for total drug content, loading efficiency, particle size 
and in vitro drug release studies. From the drug release studies it was observed 
that nanoparticles prepared with chitosan in the core: coat ratio 1:4 gives better 
sustained release for about 12 hrs as compared to other formulations. 
. 
 
. 
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DRUG PROFILE 
DESCRIPTION: 
   Imatinib mesylate is designated chemically as 4-[(4Methyl-1-
piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino] phenyl] 
benzamide methanesulfonate .  
STRUCTURE: 
 
DESCRIPTION:  
          Imatinib mesylate is a white to off-white to brownish or yellowish tinged 
crystalline powder.  
MOLECULAR FORMULA: 
       C29H31N7O • CH4SO3  
 MOLECULAR WEIGHT:  
          589.7  
SOLUBILITY: 
       Soluble in aqueous buffers ≤( pH 5.5) but is very slightly soluble to insoluble 
in neutral/alkaline aqueous buffers. In non-aqueous solvents, the drug substance is 
freely soluble to very slightly soluble in dimethyl sulfoxide, methanol and ethanol, 
but is insoluble in n-octanol, acetone and acetonitrile.   
 
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EXCIPIENTS USED: 
Colloidal silicon dioxide (NF); crospovidone (NF); hydroxypropyl 
methylcellulose (USP); magnesium stearate (NF); and microcrystalline cellulose 
(NF). Tablet coating:  ferric oxide, red (NF); ferric oxide, yellow (NF); 
hydroxypropyl methylcellulose (USP); polyethylene glycol (NF) and talc (USP). 
CLINICAL PHARMACOLOGY 
Mechanism of Action:  
          Imatinib Mesylate is a protein-tyrosine kinase inhibitor that inhibits the bcr-
abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the 
Philadelphia chromosome abnormality in Chronic Myeloid Leukemia (CML). It 
inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as 
fresh leukemic cells from Philadelphia chromosome positive chronic myeloid 
leukemia. In colony formation assays using ex vivo peripheral blood and bone 
marrow samples, imatinib shows inhibition of bcr-abl positive colonies from CML 
patients.   In vivo, it inhibits tumor growth of bcr-abl transfected murine myeloid 
cells as well as bcr-abl positive leukemia lines derived from CML patients in blast 
crisis.   Imatinib is also an inhibitor of the receptor tyrosine kinases for Platelet-
Derived Growth Factor (PDGF) and Stem Cell Factor (SCF), c-kit, and inhibits 
PDGF- and SCF-mediated cellular events. In vitro, Imatinib inhibits proliferation 
and induces apoptosis in Gastrointestinal Stromal Tumor (GIST) cells, which 
express an activating c-kit mutation. 
Pharmacokinetics: 
Imatinib is well absorbed after oral administration with Cmax achieved 
within 2-4 hours post-dose. Mean absolute bioavailability is 98%. Following oral 
administration in healthy volunteers, and its major active metabolite, the  
(N-desmethyl derivative), are approximately 18 and 40 hours, respectively. Mean 
imatinib AUC increases proportionally with increasing doses ranging from 25 mg-
1,000 mg. There is no significant change in the pharmacokinetics of imatinib on 
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repeated dosing, and accumulation is (1.5- to 2.5)-fold at steady state when 
Gleevec is dosed once daily. At clinically relevant concentrations of imatinib, 
binding to plasma proteins in in vitro experiments is approximately 95%, mostly 
to albumin and α1-acid glycoprotein.   
Metabolism and Elimination: 
CYP3A4 is the major enzyme responsible for metabolism of Imatinib 
Mesylate. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, 
and CYP2C19, play a minor role in its metabolism. The main circulating active 
metabolite in humans is the N-demethylated piperazine derivative, formed 
predominantly by CYP3A4. It shows in vitro potency similar to the parent 
imatinib. The plasma AUC for this metabolite is about 15% of the AUC for 
imatinib. The plasma protein binding of the N-demethylated metabolite 
CGP71588 is similar to that of the parent compound.  Elimination is 
predominately in the feces, mostly as metabolites. Based on the recovery of 
compound(s) after an oral 14C-labeled dose of Imatinib Mesylate, approximately 
81% of the dose was eliminated within 7 days, in feces (68% of dose) and urine 
(13% of dose).  
   Unchanged Imatinib Mesylate accounted for 25% of the dose (5% urine, 
20% feces), the remainder being metabolites.  Typically, clearance of Imatinib 
Mesylate in a 50-year-old patient weighing 50 kg is expected to be 8 L/h, while 
for a 50-year-old patient weighing 100 kg the clearance will increase to 14 L/h. 
However, the inter-patient variability of 40% in clearance does not warrant initial 
dose adjustment based on body weight and/or age but indicates the need for close 
monitoring for treatment-related toxicity.  
Drug-Drug Interactions CYP3A4 Inhibitors:  
 There was a significant increase in exposure to Imatinib Mesylate (mean 
Cmax and AUC increased by 26% and 40%, respectively) in healthy subjects when 
Gleevec was co-administered with a single dose of ketoconazole (a CYP3A4 
inhibitor).  
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CYP3A4 Substrates: 
Imatinib Mesylate increased the mean Cmax and AUC of simvastatin 
(CYP3A4 substrate) by 2- and 3.5-fold, respectively, indicating an inhibition of 
CYP3A4 . 
CYP3A4 Inducers:  
Pretreatment of 14 healthy volunteers with multiple doses of rifampin,  
600 mg daily for 8 days, followed by a single 400-mg dose of Gleevec, increased 
Gleevec oral-dose clearance by 3.8-fold (90% confidence interval = 3.5- to 4.3-
fold), which represents mean decreases in Cmax, AUC(0-24) and AUC(0-∞) by 
54%, 68% and 74%, of the respective values without rifampin treatment.  
In Vitro Studies of CYP Enzyme Inhibition:  
      Human liver microsome studies demonstrated that Gleevec is a potent 
competitive inhibitor of CYP2C9, CYP2D6, and CYP3A4/5 with Ki values of 27, 
7.5 and 8 µM, respectively. Gleevec is likely to increase the blood level of drugs 
that are substrates of CYP2C9, CYP2D6 and CYP3A4/5. 
 CLINICAL STUDIES : 
Chronic Myeloid Leukemia Chronic Phase, Newly Diagnosed: An open-
label, multicenter, international randomized Phase 3 study has been conducted in 
patients with newly diagnosed Philadelphia chromosome positive (Ph+) Chronic 
Myeloid Leukemia (CML) in chronic phase. This study compared treatment with 
either single-agent (Imatinib Mesylate) or a combination of Interferon-alfa (IFN) 
plus cytarabine (Ara-C). Patients were allowed to cross over to the alternative 
treatment arm if they failed to show a Complete Hematologic Response (CHR) at  
6 months, a Major Cytogenetic Response (MCyR) at 12 months, or if they lost a 
CHR or MCyR. Patients with increasing WBC or severe intolerance to treatment 
were also allowed to cross over to the alternative treatment arm with the 
permission of the Study Monitoring Committee (SMC).  
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POLYMER PROFILE 
HYDROXY PROPYL METHYL CELLULOSE (Raymond et al., 2003) 
Non-proprietary names 
 Hypromellose (BP), Hypromellosum and Hypromellose(USP) 
Synonyms 
 Benecel MHPC, methocel, metolese, pharmacoat,  spectracel,  tylopur 
Functional category 
 Cooling agent, film former, rate controlling polymer for SR, stabilizing 
agent, viscosity-increasing agent, tablet binder, suspending agent. 
Chemical Structure 
 
Molecular weight 
1828 
Typical properties 
pH  : 5.5-8.0(for a 1% w/v aqueous solution) 
Density   : 1.326 g/cm3 
Melting point   : browns at 190-220°c, chars at 225-230°c 
Specific gravity   :  1.26 
Incompatabilities  : with some oxidising agents  
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Description 
Odourless and bland, white or creamy white or granular powder. 
Solubility 
            Soluble in chilly water, growing a viscous colloidal resolution; usually 
insoluble in chloroform, ethanol (95%) and ether. It is soluble in mixture of 
ethanol and dichloromethane, and mixture of water and alcohol. 
Viscosity 
      Aqueous solutions are most commonly prepared. Solutions prepared using 
organic solvents are more viscous. 
Stability and storage condition 
          It is a stable material, although it is a hygroscopic afterward drying. 
Solutions are stable at pH 3-11. Upon heating and cooling, hypermellose 
undergoes a sol-gel transformation. Aqueous solutions are liable to microbial 
spoilage and should be preserved with an antimicrobial preservative. Aqueous 
solutions may also be sterilized by autoclaving; the coagulated polymer must be 
redispersed on cooling by shaking. 
  Powder ought to be stored in well closed containers. In a cool, dry locale. 
Applications  
 Used extensively in oral and topical pharmaceutical formalities.  In oral 
products, it is utilized as tablet binder in film coating and an extended release 
agent in topical formulations.  It can be utilized as an emulsifier, suspending agent 
and stabilizing agent in topical gels and ointments. 
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 In addition, it is utilized in the producing of capsules, as an adhesive in 
plastic bandages and as a wetting agent for hard contact lenses.  It is extensively 
utilized in cosmetics and food products (Wade et al., 2006) 
Method of manufacturing  
 A purified form of cellulose is reacted alongside sodium hydroxide 
solution to produce a swollen mass of alkaline cellulose that is next indulged 
alongside chloromethane and propylene oxide to produce HPMC.  The product is 
purified and ground to a fine, uniform powder or granules. 
Safety 
 Generally considered as a non toxic and non irritant material, although 
excessive oral consumption could have a laxative effect. 
Handling precautions  
 Observe normal precautions appropriate to the conditions and number of 
materials handled. 
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POLYVINYL ALCOHOL (Raymond et al., 2003) 
Non Propreitary Names 
USP: Polyvinyl alcohol 
Synonyms 
Airvol, elvanol, gohsenol, PVA, vinyl alcohol polymer 
Chemical Name And Cas Registry Number  
Ethanol, homopolymer[900-89-5] 
Empirical Formula
 
(C2H4O)n 
Chemical  Structure 
 
Molecular Weight: 
20000-200000 
 Polyvinyl alcohol is a water soluble synthetic polymer represented by 
formula (C2H4O)n.  The value of n for commercially available material lies 
between 500 and 5000, equivalent to a molecular weight range of approximately 
20000-200000. 
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Table:1 Commercially Availble Grades Of Polyvinyl Alcohol 
 
Grade Molecular Weight 
High viscosity -200000 
Medium viscosity -130000 
Low viscosity -20000 
Functional Category 
 Coating agent, lubricant, stabilizing agent and viscosity increasing agent. 
Application on Pharmaceutical Formulation or Technology  
 Polyvinyl alcohol is used primarily in topical pharmaceutical and 
ophthalmic formulation. It is used as a stabilizing agent for emulsions  
(0.25-3.0%w/v).  Polyvinyl alcohol is also used as viscosity-increasing agent for 
viscous formulations such as ophthalmic products. It is used in artificial  
tears and contact lens solution for lubrication purpose, in sustained-release 
formulation for oral administration, and in transdermal patches.  Polyvinyl alcohol 
may be made into microspheres when mixed with a gluteraldehyde solution 
(Ainley Wade et al., 2006) 
Table: 2 Uses of Polyvinyl Alcohol 
Use Concentration 
Emulsions 0.5 % 
Ophthalmic formulations 0.25-3.00 % 
Topical solutions 2.5 % 
Description 
 Polyvinyl alcohol occurs as an odourless, white to cream-colored granular 
powder. 
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Typical Properties 
Melting point: 
 228°C for fully hydrolysed grades 
 18C-190°C for partially hydrolysed grades 
Refractive Index 
N 25d=1.49-1.53 
Solubility 
 Soluble in water and insoluble in organic solvents.  Dissolution requites 
dispersion (wetting) of the solid in water at room temperature followed by heating 
the mixture to about 90°C for approximately 5 mins.  Mixing should be continued 
while the heated solution is cooled to room temperature. 
Specific Gravity  
 1.19-1.31 for solid at 25°C   
 1.02 for 10% w/v aqueous solution at 25°C 
Viscocity (Dynamic) 
Table : 3 Viscosity of commercial grades of polyvinyl alcohol  
 
Grade Dynamic Viscosity of 4%W/V Aqueous Solution at 200°C (Mpas) 
High viscosity 40.0-65.0 
Medium viscosity 21.0-33.0 
Low viscosity 4.0-7.0 
Stability and Storage Conditions 
 Polyvinyl alcohol is stable when stored in tightly sealed container in a 
cool, dry place. Aqueous solutions are stable in corrosion resistant sealed 
containers.  Preservatives may be added to the solution if extended storage is 
required.  Polyvinyl alcohol undergoes slow degradation at 100°C and rapid 
degradation at 200°C, it is stable on exposure to light. 
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Incompatibilities 
 Polyvinyl alcohol undergoes reactions typical of a compound with 
secondary hydroxyl groups such as esterification.  It decomposed in strong acid 
and softens or dissolves in weak acids and alkalis.  It is incompatible at high 
concentration at high concentration with inorganic salts, especially sulphates and 
phosphates, precipitation of polyvinyl 5% w/v can be caused by phosphates, 
gelling of polyvinyl alcohol solution may occur if borax is present . 
Method of Manufacture 
 Polyvinyl alcohol is produced through the hydrolysis of polyvinyl acetate.  
The repeating unit of vinyl alcohol is not used as the starting material because it 
can’t be obtained in the quantities and the purity required for polymerization 
purposes.  The hydrolysis proceeds rapidly in methanol, ethanol, or a mixture of 
alcohol and methyl acetate, using alkalis or mineral acids or catalysis. 
Safety 
 Polyvinyl alcohol is generally considered a non-toxic material.  It is non-
irritant to the skin and eyes at concentration up to 10% concentration up t 7% are 
used in cosmetics. 
Handling Precautions 
 Observed normal precautions appropriate to the circumstances and 
quantity of material handled.  Polyvinyl alcohol dust may be an irritant on 
inhalation.  Handle in well-ventilated environment. 
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EUDRAGIT 
 Chemical name:     Methacrylic acid 
 Chemical formula:  C4H6O2 
 Chemical structure:   
 
Synonyms:  
 2-(Methoxycarbonyl)-1-propene 
 2-Methyl-2-propenoic acid Methyl ester 
Appearance: 
         Colourless 
Odor: 
 Unpleasant 
 Acrid 
 Repulsive 
Solubility: 
 Soluble in warm water 
 Miscible with most organic solvents 
Density: 
    1.02 g/cm3 
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Molar mass: 
86.06 g/mol 
Boiling point: 
161°C 
Melting point: 
   15°C 
Applications: 
 Opthalmic drug delivery 
 Buccal and sublingual drug delivery 
 Gastrointewtinal drug delivery 
 Intestinal drug delivery 
 Colon drug delivery 
 Transdermal drug delivery 
 Vaginal drug Delivery 
 Gene delivery 
 Vaccine delivery 
           Eudragit polymer were selected for this studies because they dissolved at 
pH > 5.5 and are not soluble in acidic gastric fluid and which can prevent the pre-
mature release of the incorporated drug molecule during the preparation before 
dosing. 
          Eudragit are sufficiently begin in pre-clinical models to enable in vivo 
safety pharmacology studies where small changes in organ function and 
physiology are assessed during lead optimization.  
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MORINGA OLEIFERA  (Fuglie et al., 2001) 
Scientific classification: 
Kingdom: Plantae 
Order     : Brassicales 
Family    : Moringaceae 
Genus     : Moringa 
Species   : M. oleifera 
Synonyms: 
 Guilandina moringa L. 
 Hyperanthera moringa (L.) Vahl 
 Moringa pterygosperma 
Solubility: 
 Soluble in water. Practically insoluble in ethanol, acetone and chloroform. 
Loss on Drying:  
12.02% 
Total ash content:  
12% 
pH:  
6.8-6.9 
Viscosity:  
900cps 
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Traditional medicine and research 
The bark, sap, roots, leaves, seeds and flowers are used in traditional 
medicine. Research has examined how it might affect blood lipid profiles, 
although it is not effective at diagnosing, treating, or preventing any human 
diseases. 
Extracts from leaves contain low contents of polyphenols which are under 
basic research for their potential properties. Despite considerable preliminary 
research on the biological properties of moringa components, there are few high-
quality studies on humans to justify its use to treat human diseases.  
Potential adverse effects: 
Various adverse effects may occur from consuming moringa bark, roots or 
flowers and their extracts, as these components contain chemicals that appear to 
be toxic when eaten. Moringa leaves have been used safely in doses up to 6 grams 
daily for up to 3 weeks.  
Uses: 
           It mainly used for “TIRED BLOOD” (anemia),arthritis and other joint pain 
and it used for cancer. Moringa destroyed the cancer cell boost of the immune 
system. It reduces the toxic effect. Sometimes used as an abortifacient and to treat 
symphilis and rheumatism. 
In developing countries, moringa has the potential to improve nutrition, 
boost food security, foster rural development, and support sustainable landcare. It 
may be used as forage for livestock, a micronutrient liquid, a natural anthelmintic, 
and possible adjuvant. 
Moringa oleifera leaf powder was as effective as soap for hand washing 
when wetted in advance to enable anti-septic and detergent properties from 
phytochemicals in the leaves. 
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LINSEED 
Synonym : Flax seed. 
Biological Source: 
It consists of the dried fully ripe seeds of Linum usitatissimum Linn. 
Belonging to family Liliaceae. 
Geographical Sources: 
It is cultivated extensively as a source of fibres in Algeria, Egypt, Greece, 
Italy and Spain; as a source of oil in Afghanistan, India and Turkey; and in Russia 
(now CIS – countries) for both oil and fibre. It is also found in several temperate 
and tropical zones. 
Preparation The cyanogenetic glycoside : 
Linamarin is prepared from the defatted oil meal, seed skins or embryos of 
flax by standard methods available for glycosides. 
Description: 
Colour : Reddish brown 
Odour : Characteristic odour 
Shape : Oval and strongly flattened 
Size : Length = 4-6 mm; Width = 2-3 mm. 
Chemical Constituents : 
The ripe seeds of linseed contain small quantities of a cyanogenetic 
glycosides known as linamarin (or phaseolunatin) as given below: 
Interestingly, linamarin evolved HCN with linseed meal only but not with 
emulsin. However, pure linamarin is a bitter needle like crystalline substance. It is 
freely soluble in water, cold alcohol, hot acetone, slightly in hot ethyl acetate, 
ether, benzene, chloroform and practically insoluble in petroleum ether. 
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Besides, linseed seeds comprise of fixed oil (33-43%) mucilage present in 
testa (6%), proteins (25%) and an enzyme called linase. 
Linamarin upon enzytmatic hydrolysis yields HCN which actualy renders 
the seeds highly poisonous. 
Chemical Test : 
The mucilage of linseed seed gives a distinct red colour on being treated 
with Ruthenium Red Solution. 
Uses 
1.  Therapeutically, the linseed oil is mostly recommended for the external 
applications only; liiments and lotions. Linseed contributes to the normal 
formation of red blood cells and haemoglobin and to the reduction of 
tiredness and fatigue. Linseed intract with drug molecule it gives good 
pharmacological effect for the targeted site.  
2.  It is employed in the treatment of scabies and other skin disease in 
combination with pure flowers of sulphur. 
3.  As the linseed oil has an inherent very high ‘iodine value’ it is used mostly 
in the preparation of non staining ‘Iodine Ointment’ and several other 
products such as  ‘Cresol with Soap’. 
4.  Commercially, it is one of the most important ‘drying oil’ and therefore, 
substantially huge amounts are exclusively used for varnishes and paints. 
5.  Linseed oil finds its extensive application in the manufacturer of soap, 
grease, polymer, plasticizer, polish and linoleum. 
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 Production by country 
Top ten linseed producers – 2011 
Country Production (metric tons) Footnote 
 Canada 368,300 
 
 China 350,000 * 
 Russia 230,000 * 
 India 147,000 
 
 United Kingdom 71,000 
 
 United States 70,890 
 
 Ethiopia 65,420 
 
 Kazakhstan 64,000 * 
 Ukraine 51,100 
 
 Argentina 32,170 
 
 World 1,602,047 A 
No symbol = Official data, * = Unofficial figure, A = Aggregate (may include 
official, semi-official or estimated data) 
 
Flax seed benefits could help you improve digestion, give you clear skin, 
lower cholesterol, reduce sugar cravings, balance hormones, fight cancer and 
promote weight loss… and that’s just the beginning! Flaxseeds, sometimes called 
linseeds, are small, brown, tan or golden-colored seeds that are the richest sources 
of a plant-based omega-3 fatty acids, called Alpha Llinolenic acid (ALA) in the 
world. 
 
Polymer Profile 
   
 
 
 
Department of Pharmaceutics  54 
Nutrition Facts 
When you look at the nutritional benefits of flax seeds, there are many 
things that will catch your attention. 
A 1 ounce (3 tbsp) serving of flaxseeds contains: 
 Omega-3 (ALA)- 6,338mg 
 Fiber- 8g 
 Protein- 6g 
 Vitamin B1- 31% RDA 
 Manganese - 35% RDA 
 Magnesium -30% RDA 
 Phosphorus - 19% RDA 
 Selenium - 10% RDA 
 Also, flaxseeds contain a good amount of vitamin B6, Iron, potassium, 
 copper and zinc. 
 Flax Seed Benefits 
  High in Fiber, but Low in Carbs 
  Healthy Skin and Hair 
  Weight Loss 
  Lower Cholesterol 
  Flaxseeds are Gluten-Free 
  Flaxseeds are High in Antioxidants (Lignans) 
  Digestive Health 
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Flax Seeds for Cancer 
         Flax seed benefits have been proven time and time again and even including 
fighting breast, prostate, ovarian and colon cancer. 
 The three lignans found in flaxseeds can be converted by intestinal 
bacteria into enterolactone and enterodiol which naturally balance hormones 
which may be the reason flax seeds reduce the risk of breast cancer. 
Flaxseeds may also reduce the risk of endometrial and ovarian 
cancer.(Kajila et al., 2015) 
High in Omega-3 Fatty Acids 
           We hear a lot about the health benefits of fish oil or omega-3 fats. Fish oil 
contains EPA and DHA, two omega-3 fats that are critical for optimal health. 
Although flaxseeds do not contain EPA or DHA, they do contain ALA, another 
type of omega-3 fat. 
A study published in Nutrition Reviews has shown that 
approximately 20% of ALA can be converted into EPA, but only 5% of ALA is 
converted into DHA. Also, surprisingly gender may play a big role in conversion 
where young women had a 2.5-fold greater rate than men. 
Regardless of conversion, ALA is still considered a healthy fat and should 
be included in a balanced diet.(Kajila et al., 2015) 
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BADHAM 
Synonym: 
Badam Pisin or Almond Gum is natural edible gum obtained from the 
sweet almond tree bark. Its scientific name is Prunus amygdalus and is different 
from the Indian almond tree (Scientific name: Terminalia Catappa). 
Colour &Solubility 
       Badam Pisin is either white or brown in color and is found in the shape of 
small rocks. It can be dissolved in water and is used in making jellies.  
Badam Pisin Health Benefits and Other Uses: 
 It is edible coating on cherries and just 10% is enough to increase the shelf 
 life of the cherries for up to 15 days when stored at 2°C. 
 It has great cooling properties and is suitable for  people with excessive 
 body heat. 
 It helps calm the stomach burns, treats ulcers and reduces the burning 
 sensation in the stomach. 
 It is a good cure for people suffering from diarrhoea. 
 It is known for its cholesterol lowering properties. 
 In North India, Gondh Laddus are famous for its health benefits. It is given 
to pregnant women for its nutritional and cooling properties. It strengthens 
the bone and increases body strength. 
 It can be used in deserts and beverages after a spicy meal to prevent acidity 
 and stomach burns. 
 Being a natural gum, it is free of artificial colors and preservatives. It is 
 therefore ideal for consumption by children. 
 It can be used in preparing ice creams and jelly’s for children. 
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 It is used in uncoated tablets and is found to have increased drug release 
 property. 
 Since it is a natural gum, it is inexpensive and safe to use. 
 When consumed regularly, it helps gain weight. Add badam pisin with 
 milk and drink to see visible result in weight gain. 
SPECIAL CONSTITUENTS: 
Almond oil: 
Scientific Name(s):   
Prunus dulcis 
Family: 
        Rosaceae. 
Common Name(s): 
Almond milk, almond oil, amygdale amara, amygdalin, bittermandel, 
bitter almond, ku wei bian tao, laetrile, oil of almonds, sweet almond, vitamin 
B 17 , volatile almond oil. 
Uses: 
Almonds are used as a dietary source of protein, unsaturated fats, minerals, 
micronutrients, phytochemicals, alpha-tocopheral, and fiber, as well as in 
confectioneries. The efficacy of almonds in altering the lipid profile is weakly 
supported by the literature; larger, more robust clinical trials of longer duration are 
required. The almond derivative laetrile/amygdalin has been used as an alternative 
cancer treatment, but there is no clinical evidence to support this use. Laetrile is 
banned by the US Food and Drug Administration (FDA) and in Europe for use in 
cancer therapy. 
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Chemistry 
Almond nuts have a unique fatty acid profile, largely composed of 
unsaturated fats, some saturated fats, and no cholesterol. In addition to the protein 
and carbohydrate content, almonds contain large amounts of alpha-tocopherol and 
arginine, as well as magnesium, potassium, and sodium. Almonds are rich in 
phytosterols, including beta-sitosterol, stigmasterol, and campesterol.  The skin of 
the almond nut accounts for 4% of the total nut weight and is rich in polyphenols, 
including hydroxybenzoic acids and aldehydes, flavonol and flavanone aglycones, 
and glycosides.   
Uses and Pharmacology  
Cancer 
 Despite promising in vitro experiments, the use of amygdalin as a cancer 
treatment has not been validated by any clinical trials. The National Cancer 
Institute sponsored phase 1 and 2 clinical trials in the 1980’s but found no 
evidence to support the use of laetrile in the treatment of cancer.  Because a 
Cochrane review found no clinical trials that met adequate methodological 
quality, a meta-analysis could not be conducted. 
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COBALT (II) CHLORIDE 
Formula:   
COCl2 
Molar mass:  
129.839 g/mol 
IUPAC ID:  
Cobalt(II) chloride 
Melting point:  
735°C 
Density: 
3.36 g/cm³ 
Boiling point:  
1,049°C 
Soluble in:  
Water 
IUPAC name 
Cobalt (II) Chloride 
Other names 
Cobaltous chloride 
Cobalt dichloride 
Muriate of Cobalt 
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Properties 
Chemical formula 
CoCl2 
Molar mass 
129.839 g/mol (anhydrous) 
165.87 g/mol (dihydrate) 
237.93 g/mol (hexahydrate) 
Appearance of blue crystals (anhydrous) 
Violet-blue (dihydrate) 
Rose red crystals (hexahydrate) 
Density 
3.356 g/cm3 (anhydrous) 
2.477 g/cm3 (dihydrate) 
1.924 g/cm3 (hexahydrate) 
Melting point 
735°C (1.355°F; 1.008 K) (anhydrous) 
140°C (monohydrate) 
100°C (dihydrate) 
86°C (hexahydrate) 
Boiling point 
1049°C  
Solubility in water 
43.6 g/100 mL (0°C) 
45 g/100 mL (7°C) 
52.9 g/100 mL (20°C) 
105 g/100 mL (96°C) 
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Solubility 
38.5 g/100 mL (methanol) 
8.6 g/100 mL (acetone) 
Soluble in ethanol, ether, pyridine, glycerol . 
Magnetic susceptibility (χ) 
+12,660·10−6 cm3/mol 
Structure 
Crystal structure 
CdCl2 structure 
Coordination geometry 
Hexagonal (anhydrous) 
Monoclinic (dihydrate) 
Octahedral (hexahydrate) 
Uses: 
 Invisible ink 
 Cobalt chloride is an established chemical inducer of hypoxia-like 
 responses such as erythropoiesis. 
 Cobalt supplementation is not banned and therefore would not be detected 
 by current anti-doping testing. 
 It inhibit osteosarcoma development;the mechanism may be related to the 
hypoxic microenvironment and HIF-1α may be a critical factor and 
including inhibit proliferation, promoting apoptosis and tumor 
formation.(Bozhang et al., 2012) 
 It is a chemical inducer of hypoxia-inducible factor-1α (HIF-1α). HIF-1α 
is a transcription factor that has an important role in tumor cell  
adaptation to hypoxia, and controls the expression of several genes 
.(Yang et al., 2016) 
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OBJECTIVE 
 
    To formulate Imatinib Mesylate nanoparticles to treat leukemia, especially 
Philadelphia positive Chronic Myeloid Leukemia (ph+CML) and Chronic 
Eosinophillic Leukemia (CEL) using natural and synthetic polymers. 
     To formulate Imatinib Mesylate nanoparticles reduce severe side effects 
such as muscle cramps, stomach pain, musculoskeletal pain. 
 To reduce the frequency of dosage form, facilitate the drug targeting and 
to overcome drug resistance. To check the compatibility between the 
Imatinib Mesylate nanoparticles with natural polymers (Moringa oleifera, 
Linseed, Badam) and synthetic polymers (Poly vinyl alcohol, Hydroxy 
Propyl Methyl Cellulose, Eudragit) by FT-IR. 
 To perform the In vitro evaluation of formulated Imatinib Mesylate 
nanoparticles and optimize the formulations. 
 To complex the Imatinib Mesylate formulation with anti-proliferative 
 agent in the optimized. 
 To perform In vitro evaluation of Imatinib Mesylate nanoparticles 
complexed with Cobalt (II) Chloride. 
  To perform the acute toxicity study of Imatinib Mesylate nanoparticles 
complexation. (CoCl2 NPs) by OECD guidelines 420 using female wistar 
rat model. 
 To perform the cancer activity study of  CoCl2 NPs using to treat the male  
swiss albino mice(Dalton’s Lymphoma Ascities cell line) 
    To test the stability of the formulated Imatinib Mesylate nanoparticles. 
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BACKGROUND OF THE STUDY 
 
             Cancer is a class of diseases characterized by out-of-control cell growth. 
There are over 100 different types of cancer, and each is classified by the type of 
cell that is initially affected. Cancer harms the body when altered cells divide 
uncontrollably to form lumps or masses of tissue called tumors (except in the case 
of leukemia where cancer prohibits normal blood function by abnormal cell 
division in the blood stream). Tumors can grow and interfere with the digestive, 
nervous, and circulatory systems and they can release hormones that alter body 
function. Tumors that stay in one spot and demonstrate limited growth are 
generally considered to be benign. 
More dangerous, or malignant, tumors form when two things occur: 
1. A cancerous cell manages to move throughout the body using the blood or 
 lymphatic systems, destroying healthy tissue in a process called invasion 
2. That cell manages to divide and grow, making new blood vessels to feed 
 itself in a process called angiogenesis. 
 When a tumor successfully spreads to other parts of the body and grows, 
invading and destroying other healthy tissues, it is said to have metastasized. This 
process itself is called metastasis, and the result is a serious condition that is very 
difficult to treat.  
 Certain molecular interactions between cells and the scaffolding that holds 
cancer cells in place (extracellular matrix) cause them to become unstuck at the 
original tumor site, they become dislodged, move on and then reattach themselves 
at a new site. (Curtis et al., 2012) 
 The researchers say this discovery is important because cancer mortality is 
mainly due to metastatic tumors, those that grow from cells that have travelled 
from their original site to another part of the body. These are called secondary 
tumors. Only 10% of cancer deaths are caused by the primary tumors. 
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 Malignant cells can pass more easily through smaller gaps, as well as 
applying a much greater force on their environment compared to other cells.  
Their catalogue will help oncologists detect cancerous cells in patients 
early on, thus preventing the spread of the disease to other parts of the body.  
Cancer is ultimately the result of cells that uncontrollably grow and do not 
die. Normal cells in the body follow an orderly path of growth, division, and 
death. Programmed cell death is called apoptosis, and when this process breaks 
down, cancer begins to form. Unlike regular cells, cancer cells do not experience 
programmatic death and instead continue to grow and divide. This leads to a mass 
of abnormal cells that grows out of control. 
           In India, Cancer is thought to be the great leveler. Whether you are an 
Indian or a Korean or Icelander, cancer will bring death. But a massive study of 
26 million cancer patients over 15 years has shown that survival rates in the 10 
most prevalent types of cancer vary hugely across countries. Survival rates in 
India are quite low for most types of cancer, less than half of the advanced 
countries in many types. More surprising is the fact that survival rates in India are 
either stagnating, or inching up very slowly, despite India having some of the 
better treatment facilities. 
The ICMR has estimated that about 14.5 lakh patients will develop cancer 
in India during 2016 with the number expected to rise to 17.3 lakh by 2020. Breast 
cancer is the leading cancer in India, with an estimate of 1.5 lakh cases for 2016, 
followed by lung cancer that is expected to strike 1.14 lakh patients this year. So, 
the nanoparticles are used in the treatment of anticancer activity to target only the 
cancer cells. In this study, nanotechnology is adopted to target the cancer cells 
with the reduced side effects of Imatinib Mesylate attempted. To study to enhance 
the anti-cancerous activity of Imatinib Mesylate when complexing with anti-
prolifective agent Cobalt (II) Chloride(CoCl2 NPs) 
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MECHANISM FOR THE BIOSYNTHESIS OF COBALT METAL 
NANOPARTICLES: 
     Biosynthesis of cobalt nanoparticles in living system is catalysed by 
various reducing agents or reductase type enzymes present intracellularly or  
extracellularly. So, it is not easy to claim which compound is exactly responsible 
for biosynthesis cobalt nanoparticles in the living system. It demands research at 
molecular level. There are various theories proposed by researchers for the 
biosynthesis of  cobalt metal nanoparticles. 
1) Nanoparticles are synthesised by the reduction of metal ions to zero 
valency atom by various reductase enzyme produced by the cell, like 
nitrate reductase, which uses NADH as electron donor (Sakthivel et al., 
2010). 
 
2)  Metal ions are reduced by various reducing sugars present, or synthesised 
by microbes inside the cell, or secreted extracellularly, into zerovalent 
metal atom (Philip et al., 2010). 
         But these agents or enzymes or polymers reduce metal ion into zerovalent 
atom by the time metal ion concentration levels for the organism. So to reduse the 
toxicity of high concentration, microorganism starts reducing ions into free zero 
valent atoms. These free atoms get polarized due to free electrons. Polarization 
generates attractive force between them and binds them with metallic bond. At an 
optimum concentration of metal ions, metal nanoparticles are synthesised. If the 
concentration of added ionic solution is more than the optimum concentration  
then it will form bigger particles. Generally, due to delocalization of electron, zeta 
potential generates around the nanoparticles. In physical and chemical  
methods surfactants or polymer are used to increase the zeta potential of 
nanoparticles. (Mohanpuria et al., 2008) 
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SCOPE AND PLAN OF WORK 
 
The field of medicine never dies as long as life exists in this planet. 
Inventions and discoveries of new drug molecules are increasing from day to day 
and as a result the field of medicine is the emerging field in today’s world. Once 
the drug molecules are developed the risky phase is their moulding into different 
formulations and their route of administration. Half life, Bioavailability, firstpass 
metabolism, adverse drug reactions etc., play a major role in drug development. 
As a result drug molecules once discovered found new mouldings as the days and 
years are passed by diseases are increasing from day to day and our nature is a 
treasure hunt where still many drug molecules are yet to be discovered and 
developed. The development of drug molecules from the nature results in a 
decreased level of adverse drug reactions with increased bioavailability. 
Recent research efforts throughout the world have resulted in significant 
development of novel drug delivery systems. Among the systems one of the 
common methods of controlling the rate of drug release. The resulting 
nanoparticles have gained good acceptance as a process to achieve the sustained 
release. 
            There has been growing interest in the use of natural polymers and 
synthetic polymers as a drug carrier due to their biocompatibility, 
biodegradability, and non -toxicity and easy in availability. 
The plane of work carried out in period of 10 months (June 2016 to march 
2017) which was divided into two phases like 
Phase I 
Literature survey 
Identification of objective for the current study 
 Phase II 
   Preparation of Imatinib mesylate nanoparticles and evaluation.  
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                                  PLAN OF WORK 
 
 
 
 
 
 
 
           
          
 
 
 
Preformulation studies 
Solubility  
Studies 
FT-IR Compatibility 
studies 
Construction of 
Calibration curve  
Formulation of Nanoparticles 
Preparation of Nanoparticle formulations by solvent  evaporation method 
Characterization of Nanoparticles 
 Particle size determination. 
 Zeta potential analysis. 
 Scanning electron microscopy. 
 Entrapment efficiency 
 Raman Spectroscopy 
 XRD 
 
 In vitro  release studies 
 In vitro  Drug  release kinetics  
 
The optimized formulation complexed with CoCl2 (CoCl2 NPs) 
 Invivo studies Cancer studies  Toxicity studies 
Cancer Activity  
(Swissa albino mice)   and 
Histopathological studies (Livers) 
(S iss albino ice) and 
Acute  Toxicity (Female 
Wistar rat)   and Cytotoxicity  
( DLA) 
Materials & Equipments Used 
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MATERIALS AND EQUIPMENTS 
 
 MATERIALS USED 
 
S. No Material Source 
1 Imatinib Mesylate     Gift sample 
2 Hydroxypropyl methyl cellulose Ozone International, Mumbai 
3 Polyvinyl alcohol SD Fine Chemicals, Mumbai 
4 Eudragit SD Fine Chemicals, Mumbai 
5 Moringa oleifera gum Mothers herbs(P) Ltd, New Delhi. 
6 Linseed gum Green field Agro products, Jabalpur 
7 Badam gum Mothers herbs(P) Ltd, New Delhi. 
8 Acetone SD Fine Chemicals, Mumbai 
9 Petroleum Ether SD Fine Chemicals, Mumbai 
10 Liquid paraffin Thermo Fisher Scientific, Mumbai 
11 Cobalt(II) Chloride SD Fine Chemicals, Mumbai 
12 Trypan blue SD Fine Chemicals, Mumbai 
 
EQUIPMENTS USED 
S. No Equipment Model/Company 
1 Magnetic Stirrer REMI – 2MLH 
2 Optical Microscope MOTIC B1 SERIES 
3 UV Spectrophotometer JASCO V-530 
4 Dissolution Apparatus ELECTRO LAB TDT – 08L 
5 FT-IR Spectrometer FTIR JASCO – 4100 
6 pH meter PH Tester 1,2 (EUTECH) 
7 Zeta Sizer MALVERN 
8 SEM JSM 6390, Make – JEOL 
9 XRD Rigakuultima IV 
10 Raman Spectroscopy Shimadzu  
11 Autmotated  analyzer Orphee Mythic 18 
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EXPERIMENTAL METHODS 
 
ANALYTICAL METHOD: 
 
        A spectrophotometric method based on the measurement of absorbance at 
252 nm was used in the present study for the estimation of Imatinib Mesylate in 
the concentration range of 5-35µg/ml. Calibration curve were constructed. 
 
METHOD DEVELOPMENT  
Preparation of standard solution  
The standard stock solution of Imatinib Mesylate was prepared by 
transferring, accurately weighed 100mg of Imatinib Mesylate in 100ml of 
volumetric flask. The drug was dissolved in 50ml of distilled water under 
sonication and volume was made up to the mark using distilled water. The 
standard stock solution (1000µg/ml) was further diluted with distilled water to get 
the concentration of 10µg/ml. (Wagurkar et al., 2015) 
 
Selection of Analytical wavelength: 
            The standard solution of 10µg/ml was scanned between 200nm to 400nm 
in UV spectrophotometer against distilled water as blank after baseline correction. 
Wavelength range was selected around wavelength maxima (252nm).  
 
Procedure for plotting calibration curve of pure drug 
From the standard solution of Imatinib Mesylate was subsequently diluted 
with water to obtain a series of dilutions containing concentration in the range of 
5-35 µg/ml. The absorbance of these solutions was measured at 252 nm UV 
spectrophotometer (JASCO V530) against corresponding blank. The 
concentration of Imatinib Mesylate and the corresponding absorbance values are 
given in table. The calibration curves for the estimation of Imatinib Mesylate  
were constructed by plotting linear best fit between concentration of  
Imatinib Meslate and corresponding mean absorbance value are shown in figure:8 
(Wagurkar et al., 2015) 
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IDENTIFICATION OF IMATINIB MESYLATE 
Fourier Transform Infrared (FT-IR) Spectroscopy  
  FT-IR spectrum of drug was recorded using a FT-IR Spectra photometer 
(Shimadzu JASCO 4100). The diffuse reflectance technique was utilized in the 
mid IR 4000-400 cm-1 spectral region. The procedure consist of dispersing the 
sample in KBr (100mg) using a motor, triturating the materials into a fine powder 
bed into the holder using compression gauge. The pressure was around 5 tons for 
5 min. The pellet was placed light path and the spectrum was recorded. The 
characteristic peaks of the functional groups were interpreted.(Skoog et al., 2007) 
 
PREPARATION  OF NANOPARTICLES BY SOLVENT EVAPORATION 
METHOD: 
Imatinib Mesylate nanoparticles were prepared by using solvent 
evaporation technique which is an effective technology in preparation of Imatinib 
Mesylate nanoparticles. Accurately weighed amount of Imatinib Mesylate was 
completely dissolved in isopropyl alcohol. The obtained drug solution and 
polymer solution was then injected into the water under stirring at 3000 rpm. 
Precipitation of solid drug particles occurred immediately upon mixing. The 
suspension was centrifuged at 10000 rpm for 20 min and washed twice with 
purified water. The precipitated nanoparticles were dried for 48 hours. The 
Imatinib Mesylate nanoparticles were formulated using by various synthetic 
polymers Poly Vinyl Alcohol, Hydroxy Propyl Methyl Cellulose, Eudragit and 
natural polymers. Moringa oleifera, Badam, Linseed at 1:1,1:2 ratios respectiverly 
(F1-F12). (Mansouri et al., 2011) 
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DRUG-EXCIPIENT COMPATIBILITY STUDIES 
       Before formulating of a drug substance into a dosage form, it is essential 
that it should be chemically and physically compatibile. Compatibility studies 
give the information needed to define the nature of the drug substance and provide 
a frame work for the drug combination with pharmaceutical excipients in the 
fabrication of a dosage form. 
   One of the requirements for the selection of suitable excipients or carrier 
for pharmaceutical formulation is its compatibility. Therefore in the present work, 
a study was carried out by using infrared spectrophotometer to find out if there is 
any possible chemical interaction between Imatinib mesylate and polymers. 
    Weighed 3 mg of sample was mixed with 100 mg of potassium bromide 
(dried at 40-50˚c). The mixture was taken and compressed under 10-ton pressure 
in hydraulic press to form a transparent pellet. The pellet was scanned from  
4000-400cm-1 in IR spectrophotometer. 
          
 
CHARACTERIZATION OF NANOPARTICLES 
Scanning Electron Microscope 
A scanning electron microscopic sample holder with a double sided taps 
and coated with a layer of gold of 150˚A for 2 min using a sputter coater(JSM 
6390, Make – JEOL) in a vaccum of 3×10-1 atm of organ gas. The samples were 
then examined using a scanning electron microscope (Kumar et al., 2014). 
 
Determination of particle size  
The average mean diameters and size distribution of nanoparticle was 
found out by photon correlation spectroscopy using Zetasizer (nano ZS90, 
Malvern Instruments) at 25oC. The samples were kept in polystyrene cuvette and 
the readings were noted at a fixed angle (Kumar et al., 2014). 
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Determination of zeta potential 
The electrophoretic mobility (zeta potential) measurements of nanoparticle 
were made using Zetasizer (Nano ZS90, Malvern Instruments). The samples were 
placed in a polystyrene cuvette (at 25oC) and Zeta dip cell was used to find out the 
zeta potential (Kumar et al., 2014). 
  
Drug Entrapment Efficiency 
The prepared Imatinib Mesylate nanoparticles equivalent 250 mg were 
placed in a known quantity of solvent. After 24 hrs the samples were subjected to 
centrifugation followed by decantation of the fluid was performed to separate the 
nanoparticles containing the entrapped drug. The nanoparticles were lysed with 
isopropyl alcohol and spectrophotometric analysis was carried out at 252 nm. 
Entrapment efficiency is calculated as percentage (%) (Havanoor et al., 2014). 
𝐸݊𝑡𝑟𝑎𝑝݉݁݊𝑡 𝐸݂݂𝑖𝑐𝑖݁݊𝑐𝑦 % =  100Pr X
ContentDrugTheorital
ContentDrugactical
 
IN VITRO DRUG RELEASE:  
 The In vitro drug release profile of the prepared Imatinib Mesylate 
nanoparticles were investigated by USP Type I dissolution apparatus in using 
distilled water as dissolution medium. At a temperature of 37°C±2°C and the 
stirrer was rotated at 50 rpm speed. Nanoparticles containing Imatinib Mesylate 
equivalent 250 mg is introduced into the basket and involved in the dissolution 
medium transferred into the vessel containing 900 ml of purified water. 
 At specific intervals, 1 ml aliquot of the dissolution medium was sampled 
(the pooled sample was replaced with a fresh purified water), filtered by 
whatmann filter paper (pore size: 0.45 pm) and determine the amount of drug 
release from Imatinib Mesylate nanoparticle spectrophotometrically at 252nm by 
using Jasco V530 spectrophotometry from UV absorbance of the sample solution, 
in comparison with a standard solution having a known concentration of raw drug. 
(Mansouri et al., 2011) 
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In vitro drug release kinetics 
The drug release kinetics and mechanism of drug release of Imatinib 
mesylate nanoparticles was determined by fitting In vitro release data into various 
models such as zero order, first order and Higuchi equations Korsmeyer-Peppas 
model. 
Zero-Order Kinetics: 
 Cumulative amount of drug released was plotted against time.  
C = Kot  
 where K0 is the zero-order rate constant expressed in units of concentration/time 
and t is the time in hours. A graph of concentration Vs time would yield a straight 
line with a slope equal to Ko and intercept the origin of the axis. This kinetics 
describes concentration independent drug release from the formulations. 
First order kinetics:  
First order as log cumulative percentage of drug remaining vs time. This 
kinetics describes concentration dependent drug release from the formulations.   
Log C = Log Co-kt / 2.303 
where C0 is the initial concentration of drug, k is the first order constant, and t is 
the time. 
 
Higuchi’s Model:  
Higuchi’s model as cumulative percentage of drug released vs. square root 
of time.  
Q = Kt1/2 
where K is the constant reflecting the design variables of the system and t is the 
time in hours. This model describes the release of drug on the basis of Fickian 
diffusion as a square root of time dependent process from swellable matrix. 
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Korsmeyer-Peppas Equations:  
The mechanism of drug release, the first 60% of drug release were plotted 
in Korsmeyer equation log cumulative percentage of drug released vs log time, 
and the exponent n was calculated through the slope of the straight line,  
Mt / M∞ = Ktn 
 Where Mt/M∞ is the fractional solute release, t is the release time, K is a 
kinetic constant. Characteristic of the drug/polymer system, and n is an exponent 
that characterizes the mechanism of release of tracers. For cylindrical matrix 
tablets, if the exponent n = 0.45, then the drug release mechanism is Fickian 
diffusion, and if 0.45 <n < 0.89, then it is non-Fickian or anomalous diffusion. An 
exponent value of 0.89 is indicative of Case-II Transport or typical zero-order 
release (Balaiah. A et al.,2012). 
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COMPLEXATION OF OPTIMIZED NANOPARTICLES WITH COBALT 
(II) CHLORIDE METAL AND ITZ CHARACTERIZATION (F-13) 
The optimized Imatinib Mesylate nanoparticles were complexed with 
Cobalt(II)Chloride(CoCl2 NPs). Since Cobalt (II) Chloride posses anticancer 
activity and useful in radio immune assay, the complexation is carried out. 
 
Experimental Properties  
Complex: 
Transition elements will form co-ordination compounds (complex) 
because their d orbitals are not completely filled. In this study ligand was 
performed between F3 Formulation and cobalt (II) chloride.                         
The complex is prepared by using Equi molar (0.001M) solution of drugs 
and Cobalt (II) chloride were taken. To the drug solution was added into the 
CoCl2 solution slowly until to get the precipitation and again added to the solution 
to dissolve the precipitation to get clear solution. The clear solution was 
evaporated. Finally the complexed of crystals were formed. The complexed. The 
Imatinib Mesylate nanoparticles with Cobalt (II) Chloride (CoCl2NPs) was 
subjected to characterization, Invitro release studies and In-vivo studies. 
 
RAMAN SPECTROSCOPY: 
Light scattering phenomena may be classically described in terms of 
electromagnetic radiation produced by oscillating dipoles induced in the molecule 
by the electromagnetic fields of the incident radiation. The light scattered photons 
include mostly the dominant Rayleigh and the very small amount of Raman 
scattered light. The Induced dipole moment occurs as a result of the molecular 
polarizability α, where the polarizability is the deformability of the electron cloud 
about the molecule by an external electric field.  
In a typical Raman experiment, a laser is used to irradiate the sample with 
monochromatic radiation. Laser sources are available for excitation in the uv, 
visible, and near-IR spectral region (785 & 1064 nm). Thus, if visible excitation is 
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used, the Raman scattered light will also be in the visible region. No energy is lost 
for the elastically scattered Rayleigh light while the Raman scattered photons loss 
some energy to the specific vibrational coordinates of the sample. In order for 
Raman bands to be observed, the molecular vibration must cause a change in the 
polarizability. 
Both Rayleigh and Raman are two photon processes involving scattering 
of incident light from a virtual state. The incident photon is momentarialy 
absorbed by a transition from the ground state in to a virtual state and a new 
photon is created and scattered by a transition from this virtual state. Rayleigh 
scattering is the most probable event and the scattered intensity is ca.10-3 less than 
that of the original incident radiation. This scattered photon results from a 
transition from the virtual state back to the ground state and is an elastic scattering 
of a photon resulting in no change in energy. The CoCl2 NPs was determined by 
using raman spectroscopy. 
X-RAY DIFFRACTION: 
X-Ray diffraction is the process by which scattering of X-rays by the 
atoms of a crystal that produces an interference effect so that the diffraction 
pattern gives information on the structure of the crystal or the identity of a 
crystalline substance.  
Change in the crystalinity of the drug can be determine by this technique. 
(Opez et al., 2012) 
 
Powder X-ray diffraction study (Sagar S.Jadhav et al., 2013) 
The XRD patterns of pure drug, dummy nanoparticle and optimized 
nanoparticle are to be measured on a diffractometer. Monochromatic radiation  
(λ = 1.5418A˚), at 40 kV and 40 mA, were used as the X-ray source. The 
diffractograms were recorded between 20º and 70º with an increasing step of 
 0.02º and 2 s as the time for each step. 
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IN VIVO STUDIES 
 
EXPERIMENTAL ANIMALS:  
   Female wistar rats weighing 200-250 gm were used for acute toxicity 
studies and male swiss albino mice (20-25 mg) were used for anticancer activity. 
The animals were procured from College of Veterinary and Animal Sciences, 
Kerala Veterinary and Animal Sciences University, Mannuthy, Thrissur, Kerala, 
India. The study protocol was approved by the Institutional Animal Ethical 
Committee (COPSRIPMS/IAEC/PG/PHARAMCEUTICS/01/2015-16) and all 
procedures were conducted with proper care and use of laboratory animals. 
 
HOUSING AND FEEDING CONDITION: 
     The animals procured were acclimatized to the laboratory conditions for 7 days 
prior to the start of the experiment and they were randomized and assigned to 
various treatment groups. Studies were conducted in controlled environment under 
the temperature (22±3°C) with 12:12 hour light/dark cycle in polypropylene 
cages. Animals were provided with standard pellet feed and drinking water  
ad libitum. 
 
 ACUTE TOXICITY STUDIES: 
 Acute toxicity studies was performed following the fixed dose procedure 
employing the OECD guideline No. 420 (OECD 2002). Healthy young adult 
female rats are the commonly used laboratory strains. Normally female rats are 
used because of their sensitivity. Females should be nulliparous and non- 
pregnant. Animals should be 8-12 weeks old and weight should not deviate from  
± 20%. The animal should be fasted for 12 hour prior to the testing with free 
access to the water only. Due to absence of toxicity information for polymer in the 
sighting study one animal is administered 5 mg/kg dose and in the absence of 
toxicity 50mg/kg dose is given to second animal to check for toxicity. If no 
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mortality is observed for 50 mg/kg dose then the next dose of 300 mg/kg is given 
to third animal and if no mortality is observed then the fourth animal would 
administered with 2000 mg/kg dose. If no mortality is observed for upper dose 
limit of 2000 mg/kg, then the specific dose is selected for main study. In the main 
study another 5 animals would be dosed with 2000 mg/kg. Animals will be 
observed individually after dosing at least once during the first 30 minutes, 
periodically during the first 24 hours, with special attention given during the first 
4 hours and daily thereafter, for a total of 14 days. Keen observations should be 
done to determine the onset of signs, onset of recovery and time to death. 
Additional observations will be necessary if the animals continue to display signs 
of toxicity. Observations should include changes in skin and fur, eyes and mucous 
membranes, and also respiratory, autonomic and central nervous systems and 
behavioural pattern. 
                        Table:5 Design of acute toxicity studies 
STUDY INVOLVED DOSE(mg/kg) NO.OF.ANIMALS 
Sighting study 5 1 
Sighting study 50 1 
Sighting study 300 1 
Sighting study 2000 1 
Main study 2000 5 
 
TUMOR MAINTENANCE AND INDUCTION 
 The Ascites Dalton’s lymphoma (DLA) cell line was obtained from Amala 
Cancer Research Institute (Thrissur, India). DLA cells would be maintained  
in vivo by serial intraperitoneal transplantation of viable tumor cells   to Swiss 
albino mice (in 0.25 mL PBS, pH 7.4). For the inoculation of ascites tumors in the 
mice, DLA cells collected from the donor mouse is suspended briefly in sterile 
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isotonic saline. Viable cells is counted (Trypan blue assay) and adjusted to a 
concentration ensuring that each animal receives an Intra Peritoneal (IP) injection 
of 1×106 cells/100µl. 
Method for Diluting cell up to 106 cells/100 µl PBS 
1. Aspirate cell from tumor bearing animal (Volume taken depend upon the 
no. of animals to be induced, for ex. For 10-15 animals, 1ml of whole cell 
is sufficient). 
2. Wash the cell with PBS (Phosphate Buffered Saline, pH7.2), thrice by 
slow speed centrifugation. 
3. To the cell pellet thus obtained, add thrice volume of PBS and kept this 
suspension as stock. (If 1 ml cell pellet without blood content, add around 
3 ml PBS). 
4. Now we should further dilute the stock solution, in order to make it up to 
106  cells/ 100µl concentration. 
 
This is done by the following method, 
a. Take another test tube containing 900µl PBS. 
b. To this add 100µl cell suspension from the stock solution.  
c. This working solution then counted under microscope, under 10X 
 objective, using heamocytometer.  
d. Each corner of the hemocytometer should contain 200 cells (round, 
transparent individual cells) in order to attain the 106 cells/ 100µl 
concentration. Based on the no. of cells counted from the 100µl working 
solution, we should further dilute the stock solution.  
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IN VITRO CYTOTOXICITY STUDIES: 
Determination of in vitro cytotoxicity of Imatinib mesylate to DLA cells  
The tumor cells isolated from peritoneal cavity were washed thrice with 
phosphate buffer saline. Viable DLA cells (1×106 cells in 0.1 mL) were added to 
tubes containing various concentrations (10, 25, 50, 100 and 200 µg/mL) of 
Imatinib mesylate and the volume was made up to 1 mL using phosphate buffer 
saline (PBS). Cell viability was determined by trypan blue exclusion method  
% viability =             100
cells live ofnumber  + cells dead ofNumber 
cells dead ofNumber X  
 
EXPERIMENTAL DESIGN: 
The mice would be divided into three groups, with ten animals in each 
group: 
 Group 1 : Positive control, tumor-induced treated with pure drug Imatinib 
Mesylate (20 mg/kg/day) 
 Group 2 : Tumor-induced mice treated with Cobalt(II)Chloride  
nano particles (CoCl2 NPs) at low dose ( 200 mg/kg b.w)   in aqueous solution via 
intra-peritoneal (IP) injection for 15 days 
 Group 3 : Tumor-induced mice treated with CoCl2 NPs at high dose (400 
mg/kg b.w) in  aqueous solution via intra-peritoneal (IP) injection for 15 days.  
Animals in group I - III would be inoculated with 1×106 cells/mouse on 
day 0, and treatment with standard drug and CoCl2 NPs started 24 hours after 
transplantation. The tumor control group will be treated with the same volume of 
0.9% NaCl solution. The values for control and negative control were taken from 
PG Pharmacology Department of our college. (Sriram et al., 2010) 
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TUMOR VOLUME AND WEIGHT: 
             The mice were dissected and the ascetic fluid was collected from the 
peritoneal cavity. Volume of the fluid was measured by taking it in a graduated 
centrifuge tube and expressed in milliliter (mL).Tumor weight was measured by 
taking the weight of the mice before and after the collection of the ascetic fluid 
from peritoneal cavity and expressed in gram(g) (Dolai et al., 2015)   
 
DETERMINATION OF MEAN SURVIVAL TIME AND PERCENTAGE 
INCREASE IN LIFESPAN 
Mean survival time (MST) of each group would be noted. The MST of the 
treated groups would be compared with that of the control group using the 
following calculation: 
 
Increase in life span = (T-C/C) × 100 
where T = number of days the treated animals survived and C = number of 
days the control animals survived. 
Mean survival time (MST) in days  
=  
2
deathlast   theofday  +death first   theofday 
  
 
ILS (%) = 100
1 - group control  theof MST
 group  treated theof MST X  
 
TUMOR CELL (VIABLE/NONVIABLE) COUNT (Dolai et al., 2015)  
The ascetic fluid was taken in a WBC pipette and diluted upto 20 times 
with PBS solution. 
Then a drop of the diluted cell suspension was places on the neubauer’s 
counting chamber and the numbers of the cells in the 64 small squares were 
counted. The viability and non-viability of the cell were determined by trypan 
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blue (0.4% in normal saline) dye. The cells that did not take up the dye were 
viable and those that took the dye were nonviable. These viable and nonviable 
cells were counted by using the formula.  
Cell count = 
film) liquid of  thickness× (Area
factor)dilution  × cells of(Number 
 
EUTHANASIA OF EXPERIMENTAL ANIMALS 
After completion of the experimental treatment, all the mice would be 
deprived of food overnight and euthanized by  using excess of ketamine-xylazine 
anaesthesia. The ascitic fluid and blood samples would be collected carefully for 
various hematologic estimations, respectively. 
 HEMATOLOGIC ANALYSIS 
Blood samples of all treated groups would be collected by retro-orbital 
puncture following anaesthesia with ketamine-xylazine. The whole blood would 
be immediately collected in Ethylene Diamine Tetra Acetic-coated vials for the 
determination of WBC, RBC and platelets. (Sriram et al., 2010) 
STATISTICAL ANALYSIS: 
The results were statistically analysed by one way –ANOVA followed by 
Dunnetts test using graph pad instat software. The values were expressed as  mean 
±SEM. P<0.05 were considered statistically significant when compared to   
standard and negative control.  
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RESULTS AND DISCUSSION 
 
CONSTRUCTION OF STANDARD CURVE  
In the standard curve, linearity was obtained between 5-30 µg/ml 
concentration of Imatinib mesylate that it obeys Beer Lambert’s Law and the 
regression value was found to be r2 = 0.9992. The results are shown in table : 6 
and  Figure : 8 and 9. 
 
 
Figure : 8 UV spectra of Imatinib Mesylate 
  
max  of the  Imatinib Mesylate was determined  at 252 nm and the  UV 
spectra was determined. 
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Table:6  Concentration  of absorbance values for the estimation of 
Imatinib Mesylate at 252 nm 
S.No Concentration(µg/ml) Absorbance at 252 nm 
1 5 0.0038 
2 10 0.0075 
3 15 0.0112 
4 20 0.1580 
5 25 0.0192 
6 30 0.2101 
 
 
Figure:  9 Calibration curve  measured at the absorption of 252 nm 
 
 
 
 
Concentration g/ml 
Abs 
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INFRA RED ANALYSIS  
Compatibility studies 
FT-IR spectroscopy 
FTIR spectrum of  all formulation is given Figure : 10-254 and table  7-22. 
 
Figure :10  FTIR spectrum of pure drug – IMATINIB   MESYLATE 
        
Table:7  FTIR interpretation of pure drug 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
 
Imatinib  
mesylate 
3000-3700 3454.85 OH stretching 
1500-1700 1524.45 NH bending 
2700-3300 2781.81 CH stretching 
1300-1500 1321.96 CH bend in plane 
700-900 807.063 NH rocking 
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                                         Figure: 11 FTIR spectrum of HPMC 
Table:8  FTIR interpretation of  HPMC 
Materials Standard wave 
Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
 
 
HPMC 
3300-3600 3437.49 OH streaching 
2850-2970 2926 CH3 streaching 
1500-1760 1637 COOH streaching 
1050-1300 1118.51 C-O streaching 
600-900 613.252 C-H rocking 
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                                            Figure:12 FTIR spectrum of PVA 
 
Table:9  FTIR interpretation of  PVA 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
PVA 
3300-3600 3415.31 OH Stretching 
2850-2970 2924.52 CH3 stretching 
1500-1760 1638.23 COOH 
1340-1470 
1383.23 
1259.29 
Alkanes bending 
1050-1300 1044.23 C-O stretching 
600-900 
843.704 
611.324 
C-H rocking 
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Figure:13  FTIR spectrum of EUDRAGIT 
 
Table:10 FTIR interpretation of  EUDRAGIT 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
EUDRAGIT 
3000-3700 3455.83 OH stretching 
1500-1700 1548.56 NH bending 
2700-3300 2939.95 CH stretching 
1300-1500 1384.64 CH bending 
900-1300 966.162 C-O stretching 
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Figure: 14  FTIR spectrum of MORINGA OLEIFERA 
 
Table:11  FTIR interpretation of MORINGA OLEIFERA 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
MORINGA 
OLEIFERA 
3000-3600 3431.71 NH stretching 
1500-1700 1529.27 NH bending 
1300-1500 1384.64 CH stretching 
600-900 616.145 CH rocking 
800-1200 817.23 C-C stretching 
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                       Figure:15  FTIR spectrum of  LINSEED 
 
Table :12  FTIR interpretation of  LINSEED 
Materials 
Standard wave 
Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
LINSEED 
3000-3700 3404.71 OH stretching 
1500-1700 1547.59 NH bending 
1300-1500 1465.63 CH bending 
600-900 616.145 CH rocking 
     1600-1900 1657.52 C-O stretching 
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                       Figure:16   FTIR spectrum of  BADAM 
 
Table:13  FTIR interpretation of BADAM 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
BADAM 
3000-3700 3433.64 OH stretching 
1500-1700 1630.52 NH bending 
1300-1500 1383.68 CH bending 
600-900 616.145 CH rocking 
     1600-1900 1657.52 C-C stretching 
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Figure:17  FTIR spectrum of DRUG+HPMC 
 
Table:14  FTIR interpretation of DRUG+HPMC 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
DRUG+HPMC 
3000-3700 3442.31 OH stretching 
1500-1700 1571.7 NH bending 
1300-1500 1418.39 CH bending 
600-900 888.059 CH rocking 
     1600-1900 1660.41 C-C stretching 
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              Figure:18  FTIR spectrum of DRUG+PVA 
                          
Table:15  FTIR interpretation of DRUG+PVA 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
DRUG+PVA 
3000-3700 3427.85 OH stretching 
1500-1700 1571.7 NH bending 
1300-1500 1384.64 CH bending 
600-900 843.704 CH rocking 
     1600-1700 1662.41 C-C stretching 
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                Figure:19 FTIR spectrum of DRUG+EUDRAGIT 
                           
                   Table:16  FTIR interpretation of DRUG+EUDRAGIT 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional 
group 
assignment 
DRUG+EUDRAGIT 
3000-3700 3262.97,3004.55 OH stretching 
2700-3300 2952.48 CH bending 
1300-1500 1447.31 CH bending 
600-900 863.953 CH rocking 
     1600-1900 1657.52 C-O stretching 
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     Figure:20 FTIR spectrum of DRUG+MORINGA OLEIFERA 
 
         Table: 17 FTIR interpretation of  DRUG +MORINGA OLEIFERA 
Materials 
Standard wave 
Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
DRUG+MORINGA 
OLEFERAE 
3000-3700 3261.04 OH stretching 
2700-3300 2924.52 CH bending 
1300-1500 1473.35 CH bending 
600-900 843.704 CH rocking 
     1600-1900 1660.41 C=O stretching 
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                        Figure:21 FTIR spectrum of DRUG+LINSEED 
       
 
 
 
 
 
 
 
 
 
 
 
Figure:21 FTIR spectrum of DRUG+LINSEED 
 
 Table:18  FTIR interpretation of DRUG+LINSEED 
 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
DRUG+LINSEED 
3000-3700 3057.58 OH stretching 
1500-1700 1571.70 NH bending 
1300-1500 1372.1 CH bending 
600-900 807.063 CH rocking 
     1600-1900 1746.23 C=O stretching 
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                 Figure:22 FTIR spectrum of DRUG+BADAM 
 
Table:19 FTIR interpretation of DRUG+BADAM 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
DRUG+BADAM 
3000-3700 3734.48 OH stretching 
1500-1700 1571.7 NH bending 
1300-1500 1384.64 CH bending 
600-900 715.461 CH rocking 
     1600-1700 1660.41 C-C stretching 
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Figure:23 FTIR spectrum of DRUG+COBALT CHLORIDE(II) 
 
               Table: 20  FTIR interpretation of drug+cobalt chloride(II) 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
DRUG+COBALT 
CHLORIDE(II) 
3000-3700 3470.28 OH stretching 
1500-1700 1525.42 NH bending 
1300-1500 1321 CH bending 
600-800 620.966 C-CI stretching 
     1600-1700 1644.98 C-C stretching 
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Figure:24 FTIR spectrum of F3 FORMULATION 
(NANOPARTICLES) 
Table: 21  FTIR interpretation of F3 FORMULATION(NPs) 
Materials 
Standard wave 
Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
F3 
NANOPARTICLES 
 
 
3300-3600 3446.17 C=O stretching 
1500-1700 1507.1 NH bending 
1300-1500 1384.64 CH bending 
600-900 617.109 CH rocking 
     1600-1900 1652.70 C-C stretching 
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Figure:25 FTIR spectrum of COCL2 NPs(COMPLEX) 
 
 
   Figure:25 FTIR spectrum of F13 formulation (CoCl2 NPs) 
Table:22  FTIR interpretation of CoCl2 NPs(COMPLEX) 
Materials Standard wave Number (cm-1 ) 
Test wave 
Number (cm-1 ) 
Functional group 
assignment 
    (CoCl2 NPs) 
 
3000-3700 3315.03 OH stretching 
1500-1700 1623.77 NH bending 
1300-1500 1384.64 CH bending 
600-800 606.50 C-CI stretching 
     1600-1700 1657.52 C-C stretching 
 
From the spectra’s it can be concluded that the drug and excipient don’t 
have any incompatibility since the peaks present in the drug can also be visualized 
in the drug and excipient spectra. Hence these excipients can be chosen for the 
preparation of nanoparticles and for further ananlysis. 
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FORMULATION OF NANOPARTICLES 
Total eight formulations (F1- F12) of Imatinib mesylate nanoparticles with 
various synthetic polymers Poly Vinyl Alcohol. Hydroxy Propyl Methyl 
Cellulose, Eudragit and natural polymers Moringa oleifera, Badam, Linseed in 
this ratios were formulated and it is given in table no: 23 
 
Table:23 Formulation of Imatinib Mesylate nanoparticles 
S.no Formulation 
code Drug Polymer Drug:Polymer 
1 F1 
Imatinib 
Meylate 
HPMC 1:1 
2 F2 HPMC 1:2 
3 F3 Eudragit 1:1 
4 F4 Eudragit 1:2 
5 F5 PVA 1:1 
6 F6 PVA 1:2 
7 F7 Badam 1:1 
8 F8 Badam 1:2 
9 F9 Linseed 1:1 
10 F10 Linseed 1:2 
11 F11 Moringa oleifera 1:1 
12 F12 Moringa oleifera 1:2 
 
 
 
 
 
 
 
 
 
 
Results & Discussion 
   
 
Department of Pharmaceutics  102 
Table:24 Formulations of Imatinb Mesylate nanoparticles by solvent 
evaporation technique with various natural and synthetic polymers 
 
S. No Formulation 
code 
Weight of drug 
(mg) 
Weight of  polymers 
(mg) 
1 F1 500 500 
2 F2 500 1000 
3 F3 500 500 
4 F4 500 1000 
5 F5 500 500 
6 F6 500 1000 
7 F7 500 500 
8 F8 500 1000 
9 F9 500 500 
10 F10 500 1000 
11 F11 500 500 
12 F12 500 1000 
 
SCANNING ELECTRON MICROSCOPE ANALYSIS 
 The SEM  images were seen in different magnification starting from  
1000 X to 10000 X Surface morphology of formulated Imatinib mesylate 
nanoparticles were determined by SEM analysis which showed the small spherical 
shaped, particles without aggregation and smooth texture in surface morphology. 
In this, the formulations F1- F12 were analyzed and given in figure:26-29 
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Figure: 26 SEM Photograph of Imatinib Mesylate nanoparticle 
(formulation code F1- F4) 
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Figure:27 SEM Photograph of Imatinib Mesylate nanoparticle 
 (formulation code F5-F8) 
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Figure: 28 SEM Photograph of Imatinib Mesylate nanoparticle 
(formulation code F9- F12) 
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Figure: 29  SEM Photograph of Imatinib mesylate nanoparticle  
 with Cobalt(II) Chloride Complexation (COCL2 NPs).(F-13) 
 
                    
 
 
 
 
 
 
 
 
 
Figure: 30 SEM Photograph of Imatinib mesylate nanoparticle  
 with Cobalt(II) Chloride Complexation (COCL2 NPs).(F-13) 
 
     The surface morphology of formulated Imatinib Mesylate nanoparticles 
were determined by SEM analysis which showed the small spherical shaped, 
particles without aggregation and smooth texture in surface morphology. 
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PERCENTAGE YIELD ANALYSIS 
 Percentage yield analysis was calculated by weighing the formulated 
Imatinib meesylate nanoparticles by using the following formula. 
 Percentage yield= 100
yieldlTheoretica
yield  Practical X
 
Table :25 Percentage yield analysis of different formulations F1-F12 
S.No. Formulation Code % Yield 
1 F1 78 
2 F2 72.29 
3 F3 92 
4 F4 88.34 
5 F5 70.2 
6 F6 69.4 
7 F7 72.4 
8 F8 74.52 
9 F9 76.86 
10 F10 72.82 
11 F11 56.62 
12 F12 53.40 
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Figure: 31 Percentage yield ananlysis of different formulations F1-F12 
 
 
The percentage yield was minimum for formulation F12 (53.40%) and 
maximum for formulation F3 (92%).As the concentration of polymer increases 
percentage yield also increases. 
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DETERMINATION OF ENTRAPMENT EFFICIENCY 
Centrifugation followed by decantation of the fluid was performed to 
separate the nanoparticles containing the entrapped drug. The nanoparticles were 
lysed with isopropyl alcohol and spectrophotometric analysis was carried out at 
252 nm. Entrapment efficiency is calculated as percentage (%). 
 𝐸݊𝑡𝑟𝑎𝑝݉݁݊𝑡 𝐸݂݂𝑖𝑐𝑖݁݊𝑐𝑦 % =  100Pr X
ContentDruglTheoritica
ContentDrugactical
 
 
Entrapment Efficiency of the prepared formulation are given in Table: 26 
And Figure:32-34 
 
Table:26  Entrapment Efficiency of various formulations 
s. no Formulation code EE (%) 
1 F1 87.53 
2 F2 88.36 
3 F3 96.78 
4 F4 93.60 
5 F5 77.23 
6 F6 81.20 
7 F7 69.56 
8 F8 67.76 
9 F9 80.72 
10 F10 76.19 
11 F11 69.70 
12 F12 65.82 
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      Figure:32 Entrapment Efficiency of various formulations ratio(1:1) 
 
The Entrapment Efficiency was found to be highest for F3 formulation 
(Imatinib Mesylate: Eudragit ratio 1:1) which is 96.78% and the lowest 
entrapment of drug was found for the F7 formulation (Imatinib Mesylate: Badam 
ratio 1:1) having 69.56%. 
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Figure:33 Entrapment Efficiency of various formulations ratio(1:2) 
 
    The Entrapment Efficiency was found to be highest for F4 formulation 
(Imatinib Mesylate: Eudragit ratio 1:2) which is 93.6% and the lowest entrapment 
of drug was found for the F12 formulation(Imatinib Mesylate: Moringa oleifera 
ratio 1:2) having 65.82%. 
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Figure:34 Entrapment Efficiency of Imatinib Mesylate nanoparticles 
 
        The Entrapment Efficiency was found to be highest for F3 formulation 
(Imatinib Mesylate: Eudragit ratio 1:1) which is 96.78% and the lowest 
entrapment of drug was found for the F12 formulation (Imatinib Mesylate: 
Moringa oleifera ratio 1:2) having 65.82%. 
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PARTICLE SIZE ANALYSIS  
    Zeta size analysis of formulated Imatinib Mesylate nanoparticles are given 
in figure: 35-47 
 
Figure: 35 Zeta size distribution of F1  formulation 
 
Figure:36 Zeta size distribution of F2  formulation 
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Figure:37 Zeta size distribution of F3  formulation 
 
 
Figure:38 Zeta size distribution of F4  formulation 
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Figure:39 Zeta size distribution of F5 formulation 
 
Figure:40 Zeta size distribution of F6  formulation 
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Figure:41 Zeta size distribution of F7  formulation 
 
Figure:42 Zeta size distribution of F8  formulation 
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Figure:43 Zeta size distribution of F9  formulation 
 
 
Figure:44 Zeta size distribution of F10  formulation 
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Figure:45 Zeta size distribution of F11 formulation 
 
Figure:46 Zeta size distribution of F12  formulation 
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Figure:47 Zeta size distribution of F13  formulation (CoCl2 NPs) 
 
Table:27 Zeta size distribution of Imatinib Mesylate nanoparticles    
formulations 
S. No Formulation code Size (d.nm) 
1 F1 107.9 
2 F2 147.9 
3 F3 38.1 
4 F4 150.4 
5 F5 124.1 
6 F6 144.1 
7 F7 243.5 
8 F8 293.5 
9 F9 171.4 
10 F10 247.1 
11 F11 273.5 
12 F12 243.5 
13 F13(CoCl2 NPs) 686 
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DETERMINATION OF ZETA-POTENTIAL 
Zeta Potential was determined using Malvern zeta-sizer instrument. Zeta 
potential analysis is carried out to find the surface charge of the particles to know 
its stability during storage. Zeta potential analysis was done by producing a 
potential difference between the two electrodes. In the electrical forces are also 
acting. The ionized solid particle is surrounded by liquid ions charged oppositely 
to the surface particle. During the movement of the solid particle through the 
liquid, a liquid layer surrounding the particle will move together with it. The 
potential difference between the external surface of that shell and the liquid as a 
whole is called electro kinetic potential difference is recorded. The particle size of 
the CoCl2 NPs formulations was found. The measurement of ions on slipping 
plane of the vesicles. The value was obtained from the Figure plotted as apparent 
zeta potential vs. total counts. 
 
Figure:48  Zeta Potential for CoCl2 NPs 
The zeta potential measurement allows predictions about the stability of 
formulations. In common, particle clumb is less likely to happen for charged 
particles due to electric repulsion. The zeta potential values of the prepared 
nanoparticle revealed that they are stable. 
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IN VITRO DRUG RELEASE STUDIES 
 In vitro drug release profile data of all formulated nanoparticles are given 
in Table:28-30 and Figure: 49-51. 
   Table:28 Invitro Release profile of Imatinib Mesylate nanoparticles(F1-F6) 
S.No Time (hrs) 
Cumulative % release of drug 
F1 F2 F3 F4 F5 F6 
1 0 0 0 0 0 0 0 
2 4 18 18 23.4 18 25.2 18 
3 7 23.4 27 27 27 30.6 23.4 
4 24 45 41.4 46.8 41.4 39.6 46.8 
5 28 50.4 54 55.8 50.4 48.6 54 
6 32 63 66.6 66.6 54 55.8 59.4 
7 48 90 90 91.2 64.8 68.4 63 
 
 
 Figure:49 Release profile of Imatinib Mesylate nanoparticles(F1-F6) 
 
 
 
 
0
20
40
60
80
100
120
0 4 7 24 28 32 48
C
u
m
u
la
ti
v
e
 %
 r
e
le
a
se
Time (hrs)
CUMULATIVE % RELEASE
F1
F2
F3
F4
F5
F6
Results & Discussion 
   
 
Department of Pharmaceutics  122 
    From the in-vitro release data, it was noticed that all the prepared 
formulations had a release of 15-98% by the end of 48th hour. Initially ther was a 
fast release obtained where as a sustained effect was observed after 24th hour. The 
release data shows that the drug release was found to be approximately linear for 
the formulations (F1-F6), we can also notice that after the 32nd hour till the 48th 
hour, the release of the drug is in a sustained manner, which can be studied from 
the figure:49 
It was also found from the release data that formulations F1, F2, F3 
showed the best release of 90%, 90%, 91.2% when compared with other 
formulations. It was also noticed that for all the two types of polymers used in the 
study, the concentration of the polymer at two ratios to the was optimum and 
obtained maximum release in each category. The lowest release or sustained effect 
was observed for F4, F5, F6 formulations having a release  of 64.8%, 68.4% and 
63% respectively. 
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Table:29 Invitro Release profile of Imatinib Mesylate nanoparticles(F7-F12) 
S.No Time (hrs) 
Cumulative % release of drug 
F7 F8 F9 F10 F11 F12 
1 0 0 0 0 0 0 0 
2 4 18 9 18 18 18 9 
3 7 27 21.6 27 23.4 27 18 
4 24 45 39.6 41.4 45 36 32.4 
5 28 54 45 50.4 50.4 39.6 43.2 
6 32 57.6 55.8 54 55.8 46.8 45 
7 48 73.8 75.6 63 66.6 55.8 61.24 
 
 
Figure:50 Release profile of Imatinib Mesylate nanoparticles(F7-F12) 
 
From the in-vitro release data, it was noticed that all the prepared 
formulations had a release of 45-65% by the end of 48th hour. Initially ther was a 
fast release obtained where as a sustained effect was observed after 24th hour. The 
release data shows that the drug release was found to be approximately linear for 
the formulations (F7-F12), we can also notice that after the 32nd hour till the 48th 
hour, the release of the drug is in a sustained manner, which can be studied from 
the figure: 
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It was also found from the release data that formulations F7, F8, F10 
showed the best release of 73.8%, 75.6%, 66.6% when compared with other 
formulations. It was also noticed that for all the two types of polymers used in the 
study, the concentration of the polymer at two ratios to the was optimum and 
obtained maximum release in each category. The lowest release or sustained effect 
was observed for F9, F11, F12 formulations having a release of 63%, 55.8% and 
61.24% respectively. 
Finally, all the formulations cumulative release are noticed till 48th hour. It 
was also found from the release data that formulation F3 showed the best release 
of 91.2% when compared with other formulatios. The lowest release was observed 
for F11 formulation having a release of 55.8% respectively. 
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          Table: 30 In vitro release profile of formulation F13 (CoCl2 NPs) 
S. 
No 
Time 
(hrs) 
Absorbance 
(252 nm) 
Con.from 
Graph 
(µG/ml) 
Con. 
(µG/900
ml) 
Con. 
(Mg) 
Cumulative 
% Release 
1 0 0 0 0 0 0 
2 4 0.0126 1.2 108000 108 21.6 
3 7 0.0148 1.5 135000 135 27 
4 24 0.0280 2.7 243000 243 48.6 
5 28 0.0340 3.2 288000 288 57.6 
6 32 0.0258 3.8 342000 342 68.4 
7 48 0.0458 5.3 477000 477 95.4 
 
 
Figure: 51 Release profile of formulation F13 (CoCl2 NPs) 
   Initial cumulative percentage release for formulation F13 (CoCl2NPs) 
was 21.6% at 4 hours time and increased up to 95.4% by the end of 48th hour.The 
total release percentage by the end of 48th h was found to be 95.4%. 
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RAMAN SPECTROSCOPY: 
CoCl2 
 
 
Figure: 52 Raman Spectroscopy 
 
 
From the spectra’s it can be concluded that the drug and excipient don’t 
have any incompatibility since the peaks present in the drug can also be visualized 
in the drug and excipient spectra. Hence these excipients can be chosen for the 
preparation of nanoparticles and for further ananlysis. 
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X-RAY DIFFRACTION  
 
Figure: 53 X- Ray Diffraction  
X-Ray 40 kV , 30 mA Scan speed / Duration time 5.0000 deg./min. 
Goniometer  Step width 0.0200 deg. 
Attachment - Scan axis 2theta/theta 
Filter  Scan range 4.0000 - 100.0000 deg. 
CBO selection 
slit 
BB Incident slit 2/3deg. 
Diffrected beam 
mono. 
D/teX Ultra 
Monochro. Length limiting slit - 
Detector D/teX Ultra Receiving slit #1 2deg. 
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Figure: 53 (a) Measurement Condition 
 
Figure: 53 (b) Dendrogram 
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Figure: 53 (c) Crystallite size distribution 
IN-VITRO DRUG RELEASE KINETICS 
  From the results of in-vitro drug release kinetics it is apparent that the first 
order plots of different preparations shows linearity, as shown by their high 
regression values. The data indicates a lesser amount of linearity when plotted by 
the zero order equation. Hence, it can be concluded that the major mechanisam of 
drug release follows first order kinetics. Understanding the mechanism of drug 
release is possible by configuring the data into mathematical modeling of 
Korsmeyer-Peppas plots. Plotting of graph using percentage release vs. square 
root of time, revealed linearity. Data based on the first order models usually 
provide evidence to the diffusion mechanism of drug release from sustained 
release delivery system. 
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Figure:54 Drug release data of Formulation F13 (CoCl2 NPs) fitting to 
various kinetic models . 
 
 The release data obtained from the in-vitro dissolution study of prepared 
nanoparticles was fitted into models of Zero order, First order, Higuchi and 
Kormeyer-Peppas. Shows the respective model fitted data obtained for all the 
eight formulations studied with R2 values and exponential factor ‘n’ values. The 
overall data fitting showed that the drug release from the prepared nanoparticles 
follows Higuchi, korsmeyer-Peppas. 
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 ACUTE TOXICITY STUDIES AND SELECTION OF DOSE FOR  
IN VIVO STUDIES : 
Acute toxicity was determined as per OECD guidelines (420) employing 
fixed dose procedure for selecting the dose for biological activity. For acute 
toxicity studies female Wistar rats weighing 200-250g were taken and they were 
fasted overnight before the experimental day. Overnight fasted rats were weighed 
and body weight determined for dose calculation and the test CoCl2NPs was 
administered orally. Sighting study was conducted with a lower dose of 5 mg/kg 
using CoCl2NPs. After administration of this dose the animal was observed for 
signs of toxic effects. No toxic effect was observed and after sufficient interval of 
time (2-3 days) the second animal was administered with 50 mg/kg dose of test 
flavonoids. Similar observations were made as before and since the dose was non-
toxic the third animal was administered with 300 mg/kg. This dose also did not 
exhibit any toxicity or morbidity and therefore the last and highest dose in fixed 
dose procedure of 2000 mg/kg was administered to fourth animal. No toxicity was 
noticed for highest dose. Signs and symptoms of toxicity and death if any were 
observed individually for each rat at 0, 0.5, 1, 2, 3 and 4 h for first 24 h and 
thereafter daily for 14 days (Table 13 & 14). Diet was given to the animals after 
 4 h of dosing. The animals were observed twice daily for 14 days and body 
weight changes, food and water consumption etc., were noted. In acute toxicity 
studies, it was found that the animals were safe up to a maximum dose of  
2000 mg/kg of body weight. There were no changes in normal behavioural pattern 
and no signs and symptoms of toxicity and mortality were observed (Table 14). 
Based on the results of acute toxicity the CoCl2NPs formulation was considered 
non-toxic and 1/10th and 1/20th dose was used for the biological evaluation (anti-
cancer activity) and the studies were conducted at dose levels of 100 and  
200 mg/kg body weight. 
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Table : 31  Observations done for the Acute Oral Toxicity Study with CoCl2NPS 
Parameters observed 0 h 0.5h 1 h 2 h 4 h Day 2&3 
Day 
4&5 
Day 
6&7 
Day 
8&9 
Day 
10&11 
Day 
12&13 
Day 
14 
Respiratory 
Dyspnea - - - - - - - - - - - - 
Apnea - - - - - - - - - - - - 
Nostril discharges - - - - - - - - - - - - 
Motor 
activity 
Tremor - - - - - - - - - - - - 
Hyper activity - - - - - - - - - - - - 
Hypo activity - - - - - - - - - - - - 
Ataxia - - - - - - - - - - - - 
Jumping - - - - - - - - - - - - 
Catalepsy - - - - - - - - - - - - 
Locomotor activity  - - - - - - - - - - - 
Reflexes 
Corneal reflex - - - - - - - - - - - - 
Pinna reflex - - - - - - - - - - - - 
Righting reflex - - - - - - - - - - - - 
Convulsion Tonic and clonic 
convulsion - - - - - - - - - - - - 
Muscle tone Hypertonia - - - - - - - - - - - - Hypotonia - - - - - - - - - - - - 
Ocular sign 
Lacrimation - - - - - - - - - - - - 
Miosis - - - - - - - - - - - - 
Mydriasis - - - - - - - - - - - - 
Ptosis - - - - - - - - - - - - 
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Parameters observed 0 h 0.5h 1 h 2 h 4 h Day 2&3 
Day 
4&5 
Day 
6&7 
Day 
8&9 
Day 
10&11 
Day 
12&13 
Day 
14 
Skin 
Edema - - - - - - - - - - - - 
Skin and fur - - - - - - - - - - - - 
Erythema  - - - - - - - - - - - 
Cardiovascul
ar signs 
Bradycardia - - - - - - - - - - - - 
Tachycardia - - - - - - - - - - - - 
Piloerection 
Contraction of 
erectile tissue of 
hair 
- - - - - - - - - - - - 
Gastro 
intestinal 
signs 
Diarrhea - - - - - - - - - - - - 
 
 
 
 
Note: Acute toxicity study of  CoCl2 compound was performed and it was non-toxic up to 2000 mg/kg dose.
Live phase animals Observations  
1. Body weight every day Normal 
2. Food consumption daily Normal  
3. Water consumption daily Normal  
4. Home cage activity Normal  
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CELL VIABILITY ASSAY 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure : 55 Viable Cell Count of DLA Washing 
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Figure : 56 Viable Cell Count after drug treatment 
Table  : 32 Cell Viability Assay 
S.No. Concentration(µg/ml) % Cytotoxicity of DLA 
cells 
1 5 25 
2 10 50 
3 20 78.57 
4 40 100 
5 80 100 
  
      In vitro cytotoxicity of CoCl2 NPs was studied at concentration of 5, 10, 
20, 40 and 80µg/ml using trypan blue dye exclusion method. A concentration 
dependent decrease in percentage viability was observed. At concentration of 
10µg/ml CoCl2 NPs the percentage activity was found to be 50% and at 20µg/ml 
the percentage decrease in cell viability was found to be 78.57% and at 40 and 
80µg/ml concentration 100% decrease in cell viability noticed and IC50 value was 
found to be 10µg/ml of CoCl2 NPs. 
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Table  33 : Effect of CoCl2 on Ascitic Tumor volume, body weight and percentage  
increase in body weight 
S.No. GROUP Treatment Body 
weight(before) 
Body 
weight(after) 
% increase in body 
weight 
Tumor 
volume(ml) 
1 Control  
 
0.9% saline 
(10ml/kg) 22.2 ±1.25* 23.4±0.76* - - 
2 Negative control 0.9% saline (10ml/kg) 22.5±0.64* 37.75±1.10* - 23.92±0.6598* 
3 Standard Imatinib Mesylate (20mg/kg) 27.84±2.073# 18.44 ±1.92# 3.044±10.33# 10.28±4.36# 
4 Low dose CoCl2 NPs(200mg/kg) 23.25±1.518# 21.326±1.48# 8.39±0.5034# 2.126±0.299# 
5 High dose CoCl2 NPs(400mg/kg) 23.75±1.82# 22.426±1.738# 5.58±0.8591# 1.00±0.8591# 
 
Table : 34 Determination of mean survival time and percentage increase in lifespan 
S.No GROUP Treatment MST %ILS 
1 Negative Control 0.9% saline 12.33±0.55 60 
2 Standard Imatinib mesylate (20mg/kg) 14.23±0.76 33.3 
3 Low dose CoCl2 NPs(200mg/kg) 12.33±1.02 66.7 
4 High dose CoCl2 NPs(400mg/kg) 14.26±0.52 75 
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 The values are expressed as mean ±SEM of 10 mice in each group 
*p<0.001 when compared to control, #represents p<0.01 when compare to 
negative control and standard drug treatment. Significance of the difference 
among various group was evaluated by oneway ANNOVA followed by 
Dunnett’s test. 
The DLA control group there was significant change in body weight 
was observed between 10-12 days of treatment and on 12th day the percentage 
change in body weight was found to be 37.75±1.10 and this increase in body 
weight might be due to increase in tumor volume when compared with 0 day 
treatment 22.5±0.64. 
   Treatment with the standard drug Imatinib Mesylate the tumor volume 
was found to be 10.28±4.360 and treatment with CoCl2 NPs low dose 
(200mg/kg) drastically reduced the tumor volume to 2.126±0.299ml and with 
high dose (400mg/kg) further substantially reduced the tumor volume to 
1.00±0.8591ml. So the results uptained suggest that CoCl2 NPs at both doses 
were able to reduce tumor load compared to the standard drug and hence 
prove the effectiveness of CoCl2 NPs. 
  A similar decrease in body weight was observed in standard, low dose, 
high dose treatment with CoCl2 NPs. The results obtained with percentage 
change in body weight suggests that a decrease in tumor volume might have 
contributed to the reduction in body weight. 
The mean survival time of tumor control was found to be 12.33±0.55 
and standard as found to be 14.23±0.76 and treatment with low dose of CoCl2 
NPs(200mg/kg) was fond to be 12.33±1.02 and high dose of CoCl2 
NPs(400mg/kg) was found to be 14.26±0.52. 
The percentage increase life pan of standard was found to be 33.3% 
and treatment with low and high dose was found to be 66.7% and 75%. The 
result of this  study suggests that high dose treated CoCl2 NPs increased life 
span compared to low dose CoCl2 NPs. 
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Table  : 35 (a) Effect of CoCl2 NPs on Hematological Parameters 
Treatment Dose WBC (x109 / L) Lym% Mon% Gra% 
RBC 
(X1012/L)  Hgb% 
Control 10 ml/kg Normal 
saline-i.p 2.96 ±0.18 66.8 ±0.58 6.86  ±0.33 24.54±0.679 7.18 ±0.33 13.3 ±0.242 
Negative control 10 ml/kg Normal 
saline-i.p 11.25 ±1.63 49.25±6.00 1.77 ±0.14 45.5 ±8.026 4.47 ±0.31 11.77 ±0.69 
Low dose 
(CoCl2 NPs) 
CoCl2 
NPs(200mg/kg) 8.25 ±0.94 89.72±2.06 4.2 ±0.73 6.07 ±1.47 8.33 ±0.32 13.7 ±0.38 
High dose  
(CoCl2 NPs) 
CoCl2 
NPs(400mg/kg) 4.15 ±0.43 81.7 ±0.16 4.42 ±0.07 12.8 ±0.23 6.85 ±0.48 16.06  ±4.19 
Standard 
(Imatinib mesylate) 
Imatinib 
mesylate(20mg/kg) 62.8 ±23.9 58.8 ±8.80 14.57 ±2.86 26.54±6.036 8.15 ±0.28 12.12 ±0.335 
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Table  : 35 (b) Effect of COCL2 NPs On Hematological Parameters 
Treatment Dose HCT (%) MCV  (m X 3) MCHC(g/dL) MCH (pg) PLT  (X 109/L) 
Control 10 ml/kg Normal 
saline-i.p 35.9±0.58 48.02±0.866 35±0.46 16.28 ±0.65 741.8 ±3.35 
Negative control 10 ml/kg Normal 
saline-i.p 38.1±0.42 47.8±0.73 38.1±0.7 - - 
Low dose 
(CoCl2 NPs) 
CoCl2 NPs(200mg/kg) 44.76±1.12 53.92±1.22 30.58±0.33 16.45±0.22 781 ±31.19 
High dose  
(CoCl2 NPs) CoCl2 NPs(400mg/kg) 35.88±1.86 56.62±1.03 23.26±3.4 15.37±0.21 484 ±96.40 
Standard 
(Imatinib mesylate) 
Imatinib 
mesylate(20mg/kg) 41.68±0.9836 51.66±1.581 29.14±0.6539 14.87±0.15 821 ±64.4 
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Values are expressed mean ± SEM of six mice in each group; low dose 
and high dose are compared with standard    drug and negative control; it 
denotes P<0.01 when compared to standard significance of the difference 
among various groups was evaluated by one-way ANOVA followed by 
Dunnett’s test. 
     The effect of CoCl2NPs on various haematological parameters are 
shown in table 35:  treatment with low dose and high dose of CoCl2 NPs 
reduced the level of WBC and significantly increased the level of RBC and 
heamoglobin when compared to tumor control group. Treatment with standard 
drug significantly decreased the level of WBC and increased the RBC and 
heamoglobin when compared with the tumor control group. Similarly the 
agranular leukocytes levels such as lymphocytes and monocytes and granular 
leucocytes (neutrophils, eosinophils and basophils) levels were found to 
decreased in tumor control mice when compared to treatment groups.(low and 
high dose CoCl2 NPS and standard drug). 
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HISTOPATHOLOGY OF LIVER IN TUMOR BEARING MICE: 
    
                    Control                   Standard  
    
                   Low dose     High dose 
Figure   : 57 Histopathology of liver 
Control  - Normal lobular architecture  
Standard - Imatinib Mesylate (20mg/kg) – Altered lobular architecture  
Low dose (200mg/kg of CoCl2NPs) -  Altered lobular architecture with  
      interface hepatitis  
High dose (400mg/kg of CoCl2NPs) – Mild  Altered lobular architecture 
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Histopathology of in control mice shows normal lobular architecture 
with normal hepatocytes. There was no central vein dilation and congestion 
and with normal sinusoids. 
 The liver of standard drug treated group showed altered lobular 
architecture. The individual hepatocytes shows few cytoplasmic vacuolation 
and mild hepatitis and portal triad shows mild periportal inflammation with 
dilatation of central vein and sinusoids. 
 Treatment with low dose of CoCl2 NPs showed altered globular 
architecture in liver .The hepatocytes were found to contain cytoplasmic 
vaculation with no significant pathology of portal triads. The central vein and 
sinusoids shows mild dilatation and congestion. 
 Treatment with high dose of CoCl2 depicts almost near normal lobular 
architectcure with very mild cytoplasmic vacuolation, binucleation and 
reactive atypia in the hepatocytes. The central vein and cynocytes shows very 
mild dilatation compared with low dose and standard drug treatment group. 
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SUMMARY AND CONCLUSION 
SUMMARY 
Main objective of  in this study  to formulate Imatinib Mesylate 
nanoparticles to treat leukemia, especially Philadelphia positive Chronic Myeloid 
Leukemia (ph+ CML) and Chronic Eosinophillic Leukemia (CEL) using natural 
and synthetic polymers. Imatinib Mesylate nanoparticles reduce severe side 
effects such as muscle cramps, stomach pain, musculoskeletal pain and reduce the 
frequency of dosage form, facilitate the drug targeting and to overcome drug 
resistance. 
So the present work was aimed to formulate a novel approach to enhance 
the delivery of drug by encapsulating it into the nanoparticle system whereby the 
dose of the drug administered can be lowered to control the night time seizures. 
The present work aimed to formulate stable Imatinib Mesylate nanoparticles by 
using various synthetic and natural polymers  Poly Vinyl alcohol, Hydroxy Propyl 
Methyl Cellulose, Eudragit, Moringa oleifera, Badam, Linseed. The polymer were 
found to be economic, biocompatible and easily available. Imatinib Mesylate 
nanoparticles were prepared by using solvent evaporation method without the 
addition of surfactants and charge inducing agents, having vesicle size in the 
range of 400-800 nm. 
FTIR and UV spectral studies showed that the spectra obtained with 
sample drug were matched with standard spectra of pure drug. This shows that the 
obtained drug sample was Imatinib Mesylate. 
The FTIR spectra of pure drug and mixture of drug polymer shows that no 
appearance of additional new peak and disappearance of existing peaks of the 
drug. This indicates that there is no interaction between the drug and polymers 
used in the present study. 
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Scanning electron micrograph of the prepared nanoparticles F1-F12 are 
shown at a magnification ratio of X100,X6000. The surface morphology of the 
prepared nanoparticles was shown to be swollen and spherical.  
Vesicle size determination was carried out using Zeta-sizer F3 has the 
lowest size of 38.1 nm and F8 has maximum size of 293 nm.  
The zeta potential that was calculated and it was found that CoCl2NPs had 
the highest zeta potential of 3.71. The charge of the nanoparticles dosage form 
must be above 25 mV so as to get a stable formulation.  Since no charge inducing 
substances were added to the formulation, the zeta potential that is calculated 
solely depends upon the formulation alone. 
Entrapment efficiency of 96.78% for the formulation F3. Where as for 
formulation F12 the entrapment efficiency is found to be 65.82% of it was 
observed that when polymer concentration was increases entrapment efficiency 
will decrease. 
The sustained release patterns was observed for the prepared nanoparticles 
(F1-F13) clearly exhibiting an increase in the polymer concentration.  
          The present work aimed to form stable nanoparticles, which was prepared 
using solvent evaporation method without the addition of surfactants and charge 
inducing agents, having vesicle size in the range of 400-800 nm. Drug entrapment 
was highest for F3 formulation was 96.78%. As no charge inducing agent was 
added, the charge of the nanoparticles were below 25 mV and the highest charge 
was found to be -23mV. Finally F3 formulation complexed with CoCl2NPs 
.Maximum release was obtained for the drug release kinetics for the prepared 
formulations (F13) showed Zero order R2 =0.9476 and Higuchi release with R2 
value 0.8885 and Korsmeyer-Peppas with for (F13) R2 value 0.9815 . 
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CONCLUSION 
Imatinib Mesylate nanoparticles have been successfully prepared by 
solvent evaporation method. 
HPMC, PVA, Eudragit, Moringa oleifera, Linseed, Badam were used as 
polymers for the preparation of Imatinib Mesylate nanoparticles. 
Imatinib Mesylate nanoparticles were prepared by solvent evaporation 
method using various synthetic and natural polymers ratio of 1:1,1:2 respectively. 
Based on this physiochemical characterization in vitro drug release 
kinetics of Imatinib Mesylate nanoparticles showed 91.2% of drug at the end of  
48th hrs. The F3 formulation complexed with Cobalt (II) Chloride (CoCl2 NPs) 
(F13 gives in vitro drug release for 95.4% 
The present study was carried out to evaluate the anti-tumor effect of 
CoCl2NPs in DLA- bearing  mice. The CONPs treated animals at dose of 200 and 
400 mg/kg significantly inhibited the tumor volume, and brought back the 
haematological parameters to more or less to normal levels. In tumor control 
group, an increase in the volume of ascetic fluid was observed. Ascites fluid is the 
direct nutritional source for tumor cells and a rapid increase in volume of ascites 
fluid with tumor growth would be a means to meet the nutritional requirement of 
tumor cells. Treatment with CoCl2NPs increased the percentage the tryphan blue 
positive dead cells in tumor bearing mice. The reliable criteria for assessing the 
value of any anti-cancer drug are the prolongation of the life span of animals. The 
CoCl2NPs decreased the ascites fluid volume, viable cell count and increased the 
percentage of life span of animals. Thus, it may be concluded that the reason for 
decreasing the nutritional fluid volume and arresting the tumor growth, might be 
due to increase in life span of DLA- bearing mice. 
Summary & Conclusion 
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The major problem encountered with anti-cancer therapy are 
myelosuppression and anemia. The anemia encountered in tumor bearing mice is 
mainly due to reduction in RBC or hemoglobin levels and this may be due to iron 
deficiency or hemolysis of RBC. After the treatment with CoCl2NPs, the 
hematological parameters RBC hemoglobin and WBC counts were altered and 
this may be due the protective action of the CoCl2NPs  on the haemopoitic system. 
Based on the encouraging results, the Imatinib Mesylate (CoCl2NPs - F13) 
were found to possess good sustained release property and was able to target DLA 
cell with strong anticancer property.  
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